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ABSTRACT 
The prevalence of bicuspid aortic valve (BAV) is 1-2% and is thereby the most 
common cardiac malformation. BAV is highly associated with valvular dysfunction 
and aortic conditions such as ascending aortic aneurysm and aortic dissection. Of BAV 
individuals, 25-50% will develop indications for surgical intervention. The underlying 
molecular mechanisms of BAV formation and the reason for the high prevalence of 
ascending aortic aneurysm in these patients are unknown. 
 
The overall aim of this thesis was to characterise morphological, molecular and clinical 
aspects of BAV disease in adult patients undergoing cardiac surgery due to aortic valve 
and/or ascending aortic pathology. In the study population of this thesis more than 50% 
of the patients had a BAV. BAV patients were approximately 10 years younger than 
patients with tricuspid aortic valves (TAV) at the time of surgery. Patients that had 
additional coronary artery disease were older than patients that did not, regardless of 
whether they had a BAV or a TAV. Ascending aortic aneurysm was substantially more 
common in BAV patients than in TAV patients while aortic ectasia was equally 
common regardless of valve morphology. In patients with ascending aortic dilatation, 
aortic valve stenosis was almost exclusively associated with BAV whereas aortic valve 
regurgitation was associated with either BAV or TAV.  
 
Study I assessed the morphology of the aortic root and ascending aorta in relation to 
valve morphology and BAV phenotype (n = 300). BAV patients had larger dimensions 
of the left ventricular outflow tract and annulus than TAV patients regardless of aortic 
morphology. The relative distribution of aortic aneurysm or ectasia was not related to 
BAV phenotype. 
Study II investigated a possible association between severity of valve pathology and 
morphology of the aortic root and ascending aorta (n = 500). The combination of aortic 
valve stenosis and ascending aortic aneurysm was common in BAV patients but was 
virtually non-existent in TAV patients. Increasing severity of valve pathology was 
associated with smaller aortic dimensions. The distribution of valve pathology did not 
differ with the various BAV phenotypes. 
Study III evaluated a possible correlation between ascending aortic dilatation and 
dilatation of the distal aorta (n = 97). BAV patients with ascending aortic aneurysms 
had smaller dimensions of the distal aorta than the corresponding group of TAV 
patients. Concomitant dilatation of the descending aorta was predominantly found in 
TAV patients. 
Study IV analysed the occurrence of matrix degrading proteases in the media of the 
aortic wall (n = 109). Expression of matrix metalloproteinase 14 and 19 was associated 
with ascending aortic dilatation in TAV patients, but not BAV patients.  
Study V evaluated patient characteristics in relation to valve morphology, valve 
pathology, aortic morphology and coronary artery disease (n = 702). BAV patients with 
aortic valve pathology and/or ascending aortic dilatation rarely had concomitant 
coronary artery disease. Ascending aortic dilatation and coronary artery disease seldom 
co-existed regardless of valve morphology.  
  
SAMMANFATTNING 
Bikuspid aortaklaff (BAV) har en prevalens på 1-2% och är därmed den vanligaste 
medfödda hjärtmissbildningen. BAV är i hög grad associerad med klaffdysfunktion och 
aortapatologi såsom aortaaneurysm och aortadissektion. 25-50% av individer med 
BAV kommer att uppfylla indikation för hjärtkirurgisk intervention. De molekylära 
mekanismerna som ligger till grund för bildingen av BAV samt orsaken till den höga 
prevalensen av ascendensaneurysm som ses hos dessa patienter är inte kända. 
 
Det övergripande syftet med denna avhandling var att karakterisera morfologiska, 
molekylära och kliniska aspekter av BAV-sjukdom hos vuxna patienter som genomgår 
hjärtkirurgi till följd av aortaklaff- och/eller aorta ascendenspatologi. I den aktuella 
studiepopulationen hade mer än 50% av patienterna en BAV. BAV-patienter var cirka 
10 år yngre än patienter med en normal trikuspid aortaklaff (TAV) vid tiden för 
kirurgisk intervention. Patienter med samtidig krankärlssjukdom var äldre än de utan, 
oavsett om de hade en BAV eller en TAV. Aorta ascendensaneurysm var betydligt 
vanligare hos BAV-patienter till skillnad från ektasi av aortan som var lika vanligt hos 
BAV-patienter och TAV-patienter. Hos patienter med aorta ascendensdilatation var 
aortaklaffstenos nästan uteslutande associerat med BAV till skillnad från 
aortaklaffläckage som var associerat med BAV eller TAV.  
 
Arbete I utvärderade aortarots- och aorta ascendensmorfologi i relation till 
klaffmorfologi och BAV-fenotyp (n = 300). BAV-patienter hade större dimension på 
vänster kammares utflödestrakt och aortaannulus oavsett aortans morfologi. Den 
relativa distributionen av ascendensaneurysm eller ektasi av aortan var inte relaterad till 
BAV-fenotyp. 
Arbete II utforskade en möjlig association mellan grad av klaffpatologi och aortarots- 
och aorta ascendensmorfologi (n = 500). Kombinationen aortaklaffstenos och 
ascendensaneurysm var vanlig hos BAV-patienter men förekom mycket sällan hos 
TAV-patienter. Ökande grad av aortaklaffpatologi var associerat med mindre 
aortadimensioner. Distributionen av klaffpatologi var inte relaterad till BAV-fenotyp. 
Arbete III sökte fastställa om en korrelation mellan dilatation av aorta ascendens och 
dilatation av distala aorta förelåg (n = 97). Dimensionerna av distala aorta var mindre 
hos BAV-patienter med ascendensaneurysm jämfört med TAV-patienter med 
ascendensaneurysm. Samtidig dilatation av aorta descendens sågs i huvudsak hos 
TAV-patienter.  
Arbete IV analyserade förekomsten av matrixnedbrytande proteaser i aortaväggens 
media (n = 109). Genexpression av matrixmetalloproteinas 14 och -19 var associerat 
med aortadilatation hos TAV-patienter men inte hos BAV-patienter. 
Arbete V utvärderade patientkarakteristika i relation till klaffmorfologi, klaffpatologi, 
aortamorfologi och kranskärlssjukdom (n = 702). BAV-patienter med klaff- och/eller 
aortapatologi hade mycket sällan samtidig kranskärlssjukdom. Aorta 
ascendensdilatation och kranskärlssjukdom samexisterar sällan oavsett klaffmorfologi. 
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1 INTRODUCTION 
 
A bicuspid aortic valve (BAV) is the most common cardiac malformation with a 
prevalence of 1-2 % and is frequently associated with valvular dysfunction such as 
aortic valve stenosis and/or regurgitation (for review see 
1
). In addition, BAV is 
associated with potentially lethal aortic conditions such as ascending aortic aneurysm 
and aortic dissection. In Sweden about 100 000-200 000 individuals have a BAV. 
Approximately 50% of BAV individuals will have to undergo aortic valve surgery and 
about 25% will require ascending aortic replacement due to dilatation of the ascending 
aorta. Furthermore, having a BAV carries an eight-fold increase in the risk of aortic 
dissection.
2
 BAV-associated conditions often reach clinical significance in relatively 
young individuals and therefore not only have personal but also socioeconomic 
consequences.   
 
In view of the high number of individuals with BAV and the conditions associated with 
this malformation, surprisingly little is known about the underlying molecular 
mechanisms of BAV formation or the reason for the high prevalence of ascending 
aortic aneurysm in these patients. Both BAV formation and the associated ascending 
aortic dilatation have been linked to genetic aberrations and theories of an inherent 
weakness of the aortic wall have been proposed. In addition, rheological studies have 
shown that flow and shear stress are important factors in the development of BAV 
disease. These two main theories (i.e., genetics and hemodynamics) have generated 
several clues as to what causes BAV disease although many questions remain 
unanswered. 
 
This thesis addresses morphological, molecular and clinical aspects of BAV disease in 
adult patients undergoing cardiac surgery. The thesis aims to provide insights into the 
relation between valve morphology and aortic morphology, and possible mechanisms 
that are important in BAV-associated aneurysm formation. 
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2 BACKGROUND 
 HISTORY 2.1
A normal aortic valve is tricuspid and consists of three valvular leaflets (i.e., cusps) and 
three commissures (Fig. 1). The first recognition of a BAV, with two valvular leaflets 
and two commissures, is usually ascribed to Leonardo da Vinci (1452-1519) who drew 
a sketch of a quadricuspid, a tricuspid and a bicuspid aortic valve about 500 years ago 
(Fig. 2). Since then, the knowledge of the prevalence, clinical significance, and 
associated malformations and pathologies of BAV has grown substantially, with the 
largest contribution in recent years. The time line of historical discoveries regarding 
BAV disease is presented in Table 1. In the middle of the 19
th
 century, Paget noted 
from necropsy studies that bicuspid valves seemed to have a predilection for disease. 
Twenty years later, Peacock added to the understanding of BAV disease by reporting a 
tendency of BAVs to initially develop stenosis and, as a later consequence valvular 
incompetence. However, it was not until the end of the 19
th
 century that the clinical 
importance of a BAV was put forward by Osler who also pointed out an association of 
BAV and infective endocarditis. In the early 20
th
 century, BAV was recognised as the 
most common cardiac malformation and during the 1950s it was confirmed that valve 
stenosis in BAV disease is primarily caused by calcification and is not mainly the 
consequence of rheumatic disease. As early as 1927, Abbot commented on an 
association of BAV and aortic dissection. Sixty years later, Larson and Edwards used 
necropsy studies to report that the risk of aortic dissection is nine-fold higher in patients 
with BAV than in patients with tricuspid aortic valves (TAV). 
 
Figure 1. Aortic valve morphology 
 
 
a) Tricuspid aortic valve [www.78steps.com]; b) bicuspid aortic valve with a raphe 
(arrow); 
3
 c) unicuspid aortic valve (LMA – left main coronary artery; RCA – right 
coronary artery); 
4
 d) quadricuspid aortic valve.
3
 Panels b, c, and d are reprinted with 
permission from Elsevier. 
 
a
) 
c
) 
b
) 
d
) 
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Figure 2. Drawing by Leonardo da Vinci  
 
 
According to historians the text describes the optimal geometric properties of a 
tricuspid aortic valve in comparison with a quadricuspid valve and the sketch at the 
bottom left is thought to represent a bicuspid aortic valve (arrow).
1
 Reproduced with 
permission from Royal Collection Trust/© Her Majesty Queen Elisabeth II 2013. 
 
Table 1. Historical notes on bicuspid aortic valve disease 
 
Year Author Statement 
1512-13 Leonardo da Vinci 1 Drawing of a BAV 
1844 Paget 5 States that bicuspid valves are liable to 
disease 
1866 Peacock 6  Points out that BAVs tend to initially 
develop stenotic lesions and 
subsequently incompetence 
1886 Osler 7  
 
Stresses the clinical  importance of 
BAV and points out the malformation 
as a substrate for infective endocarditis 
1927 Abbot 8  Comments on an association between 
BAV and aortic dissection  
1928  Wauchope 9  States that BAV is the most common 
congenital anomaly of the heart 
1947 Karsner and Koletsky 10    Hypothesises that valve stenosis in 
BAV is mainly rheumatic in origin 
1953 
1955 
1959 
Campbell and Kauntze 
11
  
Smith and Matthews 
12
 
Bacon and Matthews 
13
 
Mounting evidence that BAV stenosis 
is mainly calcific and not rheumatic in 
origin 
1978 Leech et al. 14 Concludes that in the absence of other 
signs of aortic valve stenosis, a non-
diseased BAV can be identified by an 
isolated aortic ejection sound and then 
confirmed with echocardiography 
1984 Larson and Edwards 15 Shows that a BAV is a risk factor for 
aortic dissection 
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 VALVE FORMATION 2.2
In the developing human embryo, the primitive heart tube is formed in the fourth week 
of gestation and already has the ability to beat and pump the blood forward by day 22. 
The formation of the heart valves also starts around the fourth week of gestation.  
 
2.2.1 Embryology  
The division of the common outflow tract (truncus arteriosus) of the primitive heart is 
accomplished by the growth of two swellings (Fig. 3 A-B). These swellings are located 
laterally in the wall of the truncus arteriosus and grow and further fuse into a septum 
that separates the two ventricular outflow tracts (Fig. 3 B-C). Moreover, two small 
tubercles located on the tips of the truncus swellings at the inferior part of the truncus 
arteriosus are formed. These tubercles split into halves by fusion of the truncus 
swellings and give rise to the right and left valvular leaflet of the aortic and pulmonary 
valve, respectively. During fusion of the truncus swellings, an additional pair of 
tubercles are formed at the anterior and posterior part of the truncus arteriosus wall and 
these give rise to the third leaflet of the aortic- (posterior tubercle) and pulmonary 
(anterior tubercle) valve (Fig. 3 D). The valvular leaflets are formed by excavation of 
the truncal tissue (Fig. 3 E).
16
  
 
Figure 3. Fusion of the truncus swelling 
 
 
Reprinted with permission from Elsevier.
1
  
 
FIG 4   The semilunar valves develop from valve swellings of subendocardial tissue located near the luminal surface of the 
aorticopulmonary trunk (A). B-E demonstrate the morphologic changes that take place in the developing valves, a process that ...
Alan C.  Braverman , Hasan  G?ven , Michael A.  Beardslee , Majesh  Makan , Andrew M.  Kates , Marc R.  Moon
The Bicuspid Aortic Valve
Current Problems in Cardiology Volume 30, Issue 9 2005 470 - 522
http://dx.doi.org/10.1016/j.cpcardiol.2005.06.002
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The truncus swellings undergo maturation into endocardial cushions via a complex 
process. The initial swelling of the truncal tissue is caused by increased deposition of 
extracellular matrix, which is also referred to as “cardiac jelly”. The maturation 
involves not only remodelling of the extracellular matrix but also epithelial-to-
mesenchymal transformation, a process that is essential for successful valve formation, 
and the cushions will hereby be populated with valve precursor cells. The cardiac 
cushions of the outflow tract are, through migration, also populated with neural crest 
cells that contribute to the formation of the septum that separates the ventricular 
outflow tracts. The mature leaflets of the aortic valve are usually less than 1 mm thick 
and consist of three layers: the collagen-rich fibrosa located at the aortic side of the 
valve, the ventricularis with an abundance of elastin and located at the ventricular side 
of the valve, and, in between these, the spongiosa, which rich in proteoglycans.  
 
The pathogenesis of BAV formation is not known, but it is evident that the extracellular 
matrix and epithelial-to-mesenchymal transformation are essential for valvulogenesis. 
A number of signalling pathways are thought to be involved in epithelial-to-
mesenchymal transformation during valvulogenesis (Table 2) and disruptions in 
endocardial cushion formation are implicated in the pathogenesis of heart valve disease 
17
 (for review see 
18, 19
).  
 
Table 2. Principal signalling pathways and transcription factors implicated in 
epithelial-to-mesenchymal transformation in semilunar valve formation 
 
Gene Description Function 
EGF superfamily Epidermal growth factor Signalling pathway 
ErbB V-erb-b2 erythroblastic 
leukemia viral oncogene 
homolog 
Epidermal growth factor 
receptor signalling 
pathway/family of receptor 
tyrosine kinases 
NF-1 Neurofibromin 1 Ras signalling pathway 
NFATc1 Nuclear factor of T cells 
cytoplasmic 1 
Transcription factor 
NOTCH Family of transmembrane 
receptors 
Signalling pathway 
Sox9 SRY (sex determining 
region Y)-box 9 
Transcription factor 
TGF-β superfamily Transforming growth 
factor beta 
Signalling pathway 
Tbx20 T-box 20 Transcription factor 
Twist-1 Twist homolog 1 Transcription factor 
VEGF Vascular endothelial 
growth factor  
Signalling pathway 
Wnt/β-catenin Wingless type MMTV 
integration site 
family/cadherin-associated 
protein beta 
Canonical Wnt signalling 
pathway. Wnt, growth 
factor; β-catenin, co-
activator of transcription 
factors 
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2.2.2 Genetics 
2.2.2.1 Inheritance of BAV and associated cardiovascular malformations  
In 1866, Peacock suggested that BAV is congenital in origin based on findings of the 
malformation in still born foetuses and neonates with other cardiac malformations.
6
 It 
has since been confirmed that BAV is indeed related to other cardiac malformations. 
BAV is reportedly found in 25-85% of patients with aortic coarctation.
20
 Hypoplastic 
left heart syndrome and BAV co-exist and are to some extent genetically linked.
21
 
Shone’s syndrome is characterised by supravalvular mitral ring, parachute mitral valve, 
subaortic stenosis, and aortic coarctation. Bolling et al. reported that 63% (19/30) of 
their patients with Shone’s syndrome had a BAV.22 William’s syndrome is a 
neurodevelopmental disorder that is also associated with cardiovascular conditions such 
as supravalvular stenosis, peripheral pulmonary artery stenosis, aortic coarctation, and 
BAV.
23
 BAV is found in about 25% of individuals with Turner’s syndrome and is 
present in 95% of patient with Turner’s syndrome who suffer from aortic dissection.24, 
25
 BAV has been noted in conjunction with ventricular septal defects,
26
 patent ductus 
arteriosus,
27
 
28, 29
 and atrial septal defects.
29
 BAV is also associated with left coronary 
artery dominance.
30, 31
  
 
The genetic effect (heritability) on BAV formation is suggested to be as high as 89%.
32
 
BAV has an inheritance consistent with an autosomal dominant pattern with reduced 
penetrance 
33, 34
 and about 9% of first-degree relatives of BAV individuals will also 
have the malformation.
32, 35
 BAV formation has been linked to several different 
chromosomes and gene mutations, which suggests complex inheritance.
36
 
34, 37, 38
  
 
2.2.2.2 Human genes 
Since BAV is a congenital malformation, it is reasonable to expect that mutations in 
genes encoding transcription factors, extracellular matrix components, and proteins of 
signalling pathways (Table 2) that are implicated in valvulogenesis are important in 
BAV formation.
18, 19
 
 
Linkage analyses revealed an association between BAV and chromosome 9q34-35 and 
subsequently NOTCH1 in humans.
37
 NOTCH1 encodes a transmembrane receptor and 
its signalling pathway is important in developmental processes and organogenesis in a 
wide range of organisms including humans. Notch signalling is highly conserved in 
evolution and, regardless of what animal model is used, perturbations in the pathway 
inevitably lead to developmental abnormalities (for review see 
39
). Notch1 is expressed 
in endocardial cells found in the common outflow tract in mouse embryos 
40
 and Notch 
signalling is suggested to have a role in BAV formation and valve calcification.
37
 
SMAD6 (SMAD family member 6) encodes a protein that functions as a signal 
transducer and transcriptional modulator in BMP signalling (bone morphogenetic 
protein, a member of the TGF-β superfamily). Smad6 is expressed in the embryonic 
outflow tract in mice and genetic variants of SMAD6 predispose for BAV in humans.
41
 
BAV has also been linked to chromosomes 18q22, 5q21 and 13q34; however which 
specific genes within these loci are associated with BAV is unknown.
36
 The empirical 
association of BAV and hypoplastic left heart syndrome has also been confirmed 
genetically.
21
 The mutation of the inward-rectifying potassium channel Kir2.1 (KCNJ2) 
 18 
found in patients with Andersen’s syndrome (a combination of characteristic physical 
features and arrhythmias) has also been suggested in BAV disease.
38
  
 
A number of other genes are implicated in BAV formation in mice but their relevance 
in humans remains to be shown. These include Nkx2-5 (NK2 homeobox 5, transcription 
factor),
42
 Nos3 (nitric oxide synthase 3 (endothelial cells), alias eNOS),
43
 Gata5 
(GATA binding protein 5, transcription factor),
44
 and Acvr1 (activin A receptor, Type 
1, alias Alk2, member of the TGF-β superfamily).45  
 
There is a marked phenotypic variability in individuals with BAV; it is not always 
familial and/or associated with other cardiac malformations. Furthermore, not all 
individuals with BAV develop valve and/or aortic disease and therefore might remain 
unidentified.
46-48
 Thus, the genetic profiles of BAV individuals that form study 
populations in work on heritability, inheritance pattern, and gene mutations might 
represent a BAV population that is more susceptible to the associated malformations 
and conditions.
34, 37
 
 
2.2.2.3 BAV phenotype 
BAV phenotype refers to how the leaflets of a BAV are fused and whether a 
commissural raphe is present, i.e., fusion of the right and left coronary leaflets with a 
raphe (RL), fusion of the right and non-coronary leaflets with a raphe (RN), fusion of 
the left and non-coronary leaflets with a raphe (LN), and a “true” BAV with two 
equally-sized leaflets without a raphe (TB) (Fig. 4).  
 
Figure 4. BAV phenotype 
 
 
a) Tricuspid aortic valve; b) bicuspid aortic valve (RL); c) bicuspid aortic valve (RN); 
d) true bicuspid aortic valve (TB). Reprinted with permission from Oxford University 
Press (Study I).  
  
a 
c d 
b 
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BAV phenotype is suggested to have moderate heritability,
49
 meaning that the genetic 
basis of BAV phenotype is incomplete, i.e., families with several BAV individuals will 
not all have the same BAV phenotype. The aetiology of the different BAV phenotypes 
seems to differ. Mice deficient in eNOS or Gata5 develop BAV with fusion of the right 
and non-coronary leaflets.
43, 44, 50
 The RN phenotype is thought to be the result of 
perturbations in the formation of endocardial cushions of the common outflow tract that 
occurs before septation of the outflow tract.
50
 By contrast, the RL phenotype is 
suggested to be the result of an abnormal septation of the common outflow tract and to 
be linked to neural crest cell function on the basis of studies in inbred Syrian 
hamsters.
50
  
 
 BAV DISEASE 2.3
The reported prevalence of BAV varies (Table 4); however BAV is commonly referred 
to as having a prevalence of 1-2%. When summarising reports of BAV prevalence, it 
seems that 2% might be an overestimation. However, the sensitivity of identifying a 
BAV in necropsy studies and echocardiographic studies is not 100%.
51, 52
 Roberts 
reported a BAV prevalence of 0.9% in normally functioning aortic valves but the BAV 
prevalence was notably higher when diseased aortic valves were included.
53
 Of 1692 
selected military recruits that were evaluated with echocardiography by Nistri et al., 
167 were found to have a BAV.
54
 In addition, the prevalence of BAV depends on 
ethnicity and gender as BAV is more common in Caucasians and males, and these 
factors have not always been considered in analyses of BAV prevalence.
51, 55
 The male 
to female ratio of BAV is estimated to be approximately 2:1.
1, 56
 
 
BAV entails an increased risk of valvular dysfunction and aortic conditions such as 
aneurysm and dissection. BAV has an accelerated progression of valve thickening and 
calcification which is generally evident in the fourth decade of life.
51, 57, 58
 The valvular 
changes frequently progress into clinically significant valve stenosis 
59
 and it has been 
suggested that a BAV is subjected to abnormal stress even when it is clinically deemed 
to be of normal function.
60
 Excessive folding and creasing as well as asymmetrical and 
turbulent flow patterns due to a morphological “stenosis” are thought to cause increased 
stress and subsequently early failure of a BAV. Furthermore, BAV individuals are 
predisposed to infective endocarditis. The risk of bacterial colonization is greater owing 
to increased shear stress and subsequent endothelial damage which in turn leads to 
platelet aggregation and fibrin deposition. Microorganisms tend to adhere to and 
multiply in these platelet-fibrin vegetations 
61
 
62, 63
 (for review see 
64
). BAV phenotype 
has been proposed to affect the susceptibility for valve disease; BAV individuals with a 
RN configuration are prone to develop valve disease in childhood, whereas BAV 
individuals with a RL configuration tend to develop valve disease in adulthood.
49
 
Alltogether approximately 50% of individuals with BAV will have to undergo aortic 
valve surgery.
2
 
 
The BAV-associated aortic conditions (aneurysm/dissection) are potentially lethal if 
left untreated. BAV individuals have an age-adjusted relative risk of aneurysm 
formation of approximately 86 in comparison with the general population and about 
25% of BAV individuals will develop indication for ascending aortic replacement.
2
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Table 4. Reported prevalence of BAV 
 
Author, 
study type 
Study 
pop. (n) 
Age 
 
Male: 
female 
Ethnicity (%) BAV (%) 
Osler 1886, 
necropsy 7 
> 800 8 m-60 y 3.5:1 _ 2.3 
Lewis et al. 1923, 
necropsy 65 
215 _ _ _ 1.39 
Wauchope 1928, 
necropsy 9 
9 966 
33.6 ± 
20.1 y 
4:1 _ 0.5 
Roberts 1970, 
necropsy 53 
1 440 15-79 y 3:1 _ 0.9 (-2) 
Larson et al. 
1984, necropsy 15 
21 417 _ _ _ 1.37 
Datta et al. 1988, 
necropsy 66 
8 800 8-70 y 11:1 _ 0.59 
Pauperio et al. 
1999, necropsy 51 
2 000 3 m-68 y All male 
White, 0.93; 
mulatto, 0.6 
black 0 
0.65 
Basso et al. 2004, 
echocardiography 
67 
817 10 y 3:1 _ 0.5 
Tutar et al., 
echocardiography 
68 
1 075 
Neonates 
(27-42 w) 
4:1 _ 0.46 
Nistri et al., 
echocardiography 
54 
20 946 18 ± 2 y 
Only 
males 
included 
_ 0.8 
m – months; w – weeks; y – years.  
 
Aortic dissection is caused by disruption of the internal layer of the aortic wall, which 
results in bleeding between the aortic wall layers and creation of a dissection plane. The 
condition is associated with malperfusion of vital organs and predisposes for aortic 
rupture.
69
 The risk of aortic dissection is eight-fold higher in BAV individuals than in 
the general population.
2
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BAV is usually asymptomatic in children and young adults and is commonly an 
incidental finding. Symptoms and physical findings associated with BAV are mainly 
related to the associated valvular and aortic conditions. Aortic valve stenosis is the 
dominating valve pathology in BAV patients followed by valve regurgitation (not 
secondary to infective endocarditis) and finally endocarditis.
48, 70
 Ascending aortic 
dilatation is rarely symptomatic whereas aortic dissection is usually associated with an 
acute onset of severe chest and/or back pain and is accompanied by signs of organ 
dysfunction and shock.  
 
2.3.1 Aortic valve stenosis 
Aortic valve stenosis is the most frequent valvular dysfunction associated with BAV.
70
 
The underlying mechanisms of aortic valve stenosis formation are believed to be 
similar to those of atherosclerosis (for review see 
71
). A number of risk factors that are 
associated with aortic valve calcification have been identified and these are similar to 
those of atherosclerotic disease (demographic: advanced age and male gender; clinical: 
cigarette smoking, diabetes, and hypertension; biochemical: total cholesterol, raised 
low-density lipoprotein cholesterol, raised triglycerides, low high-density lipoprotein 
cholesterol, raised lipoprotein (a), uraemia, raised serum creatinine, and raised serum 
calcium ); however, the distinction between BAV and TAV has not been made.
72, 73
 
Even though BAV patients present with significant valve stenosis earlier in life than 
patients with TAV, the pathogenesis of the valve lesion is thought to be similar, but not 
identical.
74-76
 eNOS deficiency and signalling pathways such as Notch and Wnt/β-
Catenin, which are implicated in BAV formation, have also been suggested to be 
important in valve calcification, possibly providing a link between the malformation 
and its most frequent valvular pathology.
37, 77, 78
 However, valve pathology in BAV 
individuals is suggested to mainly be the result of non-genetic factors on the basis of 
human genetic studies.
49
  
 
An association between aortic valve disease and BAV phenotype has been proposed; 
however there are conflicting results. Beppu et al. found a more rapid progression of 
valve stenosis in BAVs with an anterioposterior location (i.e., RL) in patients aged 15-
76 years.
58
. Moreover, Fernandes et al.found an association between valve disease 
(both stenosis and regurgitation) and BAVs with a RN configuration in patients aged 1 
day-17.9 years.
79
. By contrast, BAV phenotype was not found to be an independent 
predictor of cardiac events (including aortic valve disease) by Tzemos et al.
70
 
 
2.3.2 Aortic valve regurgitation 
Aortic valve regurgitation is the second most common valvular lesion associated with 
BAV and is often secondary to valve calcification. BAV patients with isolated valve 
regurgitation are in general younger than those with combined valve 
stenosis/regurgitation. Further mechanisms of incompetence include incomplete closure 
of leaflets, redundancy of the fused leaflets leading to prolapse, infective endocarditis, 
dilatation of the aortic root, and aortic dissection.
51, 54, 63, 80-82
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2.3.1 Aortic pathology 
The wall of the aorta consists of three basic layers: the internal layer, tunica intima, 
which contains a single layer of endothelial cells and a thin layer of connective tissue; 
the middle layer, tunica media, which mainly contains vascular smooth muscle cells, 
elastic fibres and collagen; and the outer layer, tunica adventitia, which predominantly 
contains collagen. The intima and the media are separated by the tunica elastica interna 
and the media is separated from the adventitia by the tunica elastic externa.
83
  
 
The aortic media is arranged in lamellar units where two elastic lamellae enclose 
vascular smooth muscle cells. The smooth muscle cells are surrounded by extracellular 
matrix that contains microfibrils, small elastic fibres, collagen, and proteoglycans. The 
extracellular matrix interconnects the two elastic lamellae as well as connecting the 
elastic lamellae with the smooth muscle cells.
84-86
 Elastin fibres from the lamellae 
protrude between thick collagen fibres (containing collagen I, III, and V) and together 
with microfibrils of fibrillin-1 and collagen VI (also containing some fibronectin) 
facilitates the smooth muscle cell-elastin interaction.
87
 Histological changes of the 
aortic wall related to age as well as aortic pathology (dilatation/dissection) are 
associated with medial degeneration, regardless of aortic location (i.e., ascending, 
descending, or abdominal).
88, 89
 Medial degeneration includes fragmentation of elastic 
fibres, rarefication of smooth muscle cells and areas of mucoid degeneration (possibly 
constituted by intact or modified glycosaminoglycans).
85
 Although there are no evident 
qualitative differences in medial degeneration related to age, type of aortic pathology, 
or aortic location, quantitative differences are evident and BAV patients have more 
severe histological changes than TAV patients.
90, 91
 Furthermore, elastic fragmentation 
is more pronounced in BAV patients than in TAV patients with isolated valve 
pathology 
92
 and an association of BAV phenotype and the severity of medial 
degeneration has been reported.
93
  
 
The pathogenesis of aortic dilatation and aneurysm formation of the ascending, 
descending, and abdominal aorta differs.
94, 95
 Experimental studies have shown that the 
embryonic origin of the cells populating the aorta in mammals differs with the aortic 
location. Neural crest cells give rise to the ascending aorta, aortic arch, pulmonary 
trunk, and ductus arteriosus. By contrast, cells originating from the mesoderm populate 
the descending aorta and subclavian artery 
96,
 
97
 (Fig. 5). Whether developmental 
differences have an impact on differences in the underlying pathogenesis of aortic 
dilatation related to aortic location (i.e., ascending, descending, abdominal) is not 
known. However, aneurysm formation is on a progressive scale (ascending < 
descending < abdominal) associated with atherosclerosis and inflammation.
98, 99
 
Furthermore, ascending aortic dilatation in TAV, but not BAV, is associated with 
inflammation and immune response.
100
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Figure 5. Developmental origin of cells populating the ascending aorta 
 
 
Experimental studies in mice. Green represents LacZ-positive neural crest cells. aAo – 
aortic root; INN – innominate artery; LCA – left carotid artery; LSCA – left subclavian 
artery; PT- pulmonary trunk; RCA – right carotid artery; RSCA – right subclavian 
artery. Reprinted with permission from Nature review and The Company of Biologists 
© Jiang et al. Development 127, 1607-1616 (2000).
97, 101
 
 
In addition to differences in the severity of medial degeneration and inflammatory 
profile between BAV and TAV patients with aortic dilatation, several other factors 
related to BAV-associated aortic dilatation have been reported as follows: I) dilatation 
of the ascending aorta is progressive in BAV, but not in TAV, regardless of aortic valve 
replacement;
102, 103
 II) children (and young adults) with BAV have larger dimensions of 
the aortic root/ascending aorta and impaired aortic elastic properties compared with 
children with TAV;
67, 104, 105
 III) approximately one third of first degree relatives of 
BAV patients (with normally functioning TAVs) have dilated aortic roots and abnormal 
elastic properties of the aorta;
106
 IV) there are differences in signalling pathways 
involved in extracellular matrix homeostasis between BAV and TAV patients with 
dilated aortas 
107-114
 (Study IV); V) eNOS expression is lower in BAV patients than in 
TAV patients and is inversely correlated with aortic diameter;
115
 and VI) mutations in 
genes encoding components of the extracellular matrix are linked to aortic dilatation 
and BAV (Table 5). 
Figure 5 Developmental origin of cells populating the ascending aorta
El-Hamamsy I and Yacoub M H (2009) Cellular and mol cular echanisms of tho acic aortic aneurysms
Nat Rev Cardiol doi:10.1038/nrcardio.2009.191
Permission obtained from The Company of Biologists © Jiang et al. Development 127, 1607–1616 (2000).
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Table 5. Human genes encoding extracellular matrix components associated with 
aortic dilatation and BAV 
 
Gene Description Function 
FBN1 113, 121 Fibrillin 1 Extracellular matrix 
glycoprotein, forms 
microfibrils, structural 
component , provides 
force-bearing support 
ACTA-2 122 Actin alpha-2 Member of the actin 
family of proteins, major 
constituent of contractile 
elements 
TGFBR2 121 Transforming growth factor, 
beta receptor II 
Transmembrane 
receptor with a protein 
kinase domain, 
phosphorylates proteins 
 
Many aspects of what causes BAV formation and subsequent BAV disease are not 
known, but there are two predominating theories, i.e., genetics and haemodynamics. 
The morphology of a BAV is evidently different from that of a normal TAV with the 
consequence of altered flow across the valve.
116
. The abnormal flow patterns are 
thought to predispose patients to aortic dilatation mediated by increased shear stress 
and differential gene expression in the aortic wall.
109, 111, 117
 An intrinsic “stenotic” state 
of a non-calcified BAV combined with accelerated progression of valve disease in 
BAVs is suggested to add to the hemodynamic stress that the aorta is subjected to.
51, 57-
60
 However, findings such as progressive dilatation of the ascending aorta after aortic 
valve replacement in BAV patients but not in TAV patients, aortic dilatation out of 
proportion to existing valve lesions in both children and adults with a BAV, and a 
reduction of extracellular matrix components of the aortic media in BAV patients has 
led to the notion of an inborn weakness of the aorta in BAV individuals.
56, 103, 113, 118, 119
 
Several molecular pathways involved in extracellular matrix integrity of the aortic 
media have been investigated and more recently defective repair mechanisms have 
been suggested to be important in BAV-associated aortic dilatation 
111, 112
 (for review 
see 
120
). 
   
2.3.1.1 Matrix metalloproteinases 
Matrix metalloproteinases (MMPs) constitute a family of enzymes that have the ability 
to degrade components of the extracellular matrix (for review see 
123
). MMPs are 
expressed in several different cell types such as endothelial cells, leukocytes, 
macrophages, fibroblasts, and vascular smooth muscle cells. There are more than 
twenty different known human MMPs and four endogenous tissue inhibitors of 
metalloproteinases (TIMPs) (Table 6). The tissue distributions and functions of several 
of these enzymes are only known to a limited extent. However, MMPs are implicated 
as mediators of altered turnover of the extracellular matrix in the media of dilated or 
aneurysmatic aortas. 
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Table 6. Members of the MMP family in humans 
 
MMP Alias Common substrates 
MMP1 Interstitial collagenase, 
Collagenase 1  
Collagen I, II, III, VII, VIII, X, aggrecan, 
gelatin, MMP2, -9 
MMP2 Gelatinase A Collagen I-V, VII, X, XI, aggrecan, 
elastin, fibronectin, gelatin, laminin, 
proteoglycan, MMP9, -13 
MMP3 Stromelysin 1 Collagen II, III, IV, IX, X, XI, aggrecan, 
elastin, fibronectin, gelatin, laminin, 
proteoglycan, MMP7, -8, -13 
MMP7 Matrilysin 1 Collagen IV, X, aggrecan, elastin, 
fibronectin, gelatin laminin, proteoglycan, 
MMP1, -2, -9 
MMP8 Neutrophil collagenase, 
Collagenase 2 
Collagen I, II, III, V, VII, VIII, X, 
aggrecan, elastin, fibronectin, gelatin, 
laminin 
MMP9 Gelatinase B Collagen IV, V, VII, X, IVX, aggrecan, 
elastin, fibronectin, gelatin 
MMP10 Stromelysin 2 Collagen III-V, aggrecan, elastin, 
fibronectin, gelatin, laminin, MMP1, -8 
MMP11 Stromelysin 3 Aggrecan, fibronectin, laminin 
MMP12 Macrophage elastase Collagen IV, elastin, fibronectin, gelatin, 
laminin 
MMP13 Collagenase 3 Collagen I-IV, aggrecan, gelatin 
MMP14 
(MT1-MMP) 
Membrane-type-1 
matrix 
metalloproteinase 
Collagen I, II,III, aggrecan, elastin, 
fibronectin, gelatin, laminin, MMP2, -13 
MMP15 
(MT2-MMP) 
Membrane-type-2 
matrix 
metalloproteinase 
Collagen I, fibronectin, gelatin, laminin, 
MMP2 
MMP16 
(MT3-MMP) 
Membrane-type-3 
matrix 
metalloproteinase 
Collagen I, MMP2 
MMP17 
(MT4-MMP) 
Membrane-type-4 
matrix 
metalloproteinase 
Fibrin, gelatin 
MMP19 RASI-1 Collagen IV, fibronectin, aggrecan, 
COMP, laminin, gelatin 
MMP20 Enamelysin  Collagen V, aggrecan, amelogenin, 
cartilage oligomeric matrix protein 
 26 
MMP21 _ α1-Anti-trypsin 
MMP23 _ _ 
MMP24 
(MT5-MMP) 
Membrane-type-5 
matrix 
metalloproteinase 
Fibrin, gelatin 
MMP25 
(MT6-MMP) 
Membrane-type-6 
matrix 
metalloproteinase 
Collagen IV, gelatin, fibronectin, laminin, 
fibrin 
MMP26 Matrilysin 2 Collagen IV, gelatin, fibronectin 
MMP27 _ _ 
MMP28 Epilysin Casein  
Reprinted with permission from Elsevier.
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3 AIMS 
 
The overall aim of this thesis was to characterise morphological, molecular, and clinical 
aspects of BAV disease in adult patients undergoing cardiac surgery. 
 
Specific aims:  
 
1. To assess the morphology of the aortic root and ascending aorta in relation to 
 valve morphology and BAV phenotype (Study I) 
 
 
2. To investigate a possible association between the severity of valve pathology 
 and the morphology of the aortic root and ascending aorta (Study II) 
 
 
3. To evaluate a possible correlation between ascending aortic dilatation and 
 dilatation of the remaining aorta (Study III) 
 
 
4. To analyse the occurrence of matrix-degrading proteases in the media of the 
 aortic wall (Study IV) 
 
 
5. To evaluate patients characteristics in relation to valve morphology, valve 
 pathology, aortic morphology, and coronary artery disease (Study V) 
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4 METHODS 
 ADVANCED STUDY OF AORTIC PATHOLOGY (ASAP) 4.1
ASAP is a prospective study that enrolled 600 consecutive patients undergoing elective 
cardiac surgery due to aortic valve and/or pathology of the aortic root and/or ascending 
aorta at the Cardiothoracic Surgery Unit at Karolinska University Hospital (Fig. 6).  
 
Figure 6. Flowchart of patients included in ASAP 
 
 
 
Exclusion criteria: < 18 years old; unable to give informed consent; significant 
coronary artery disease (i.e., significant stenosis at coronary angiogram); other 
concomitant valve surgery indicated; acute intervention indicated; previous cardiac 
surgery; blood-borne infection.*
)
 These patients were excluded due to logistic reasons 
(n = 4), discovery of existing exclusion criteria (n = 7), other medical reasons (n = 6), 
and patient withdrawal (n = 10). 
 
The preoperative screening included cardiovascular risk factor profiling, medical 
history, medication, laboratory findings and echocardiographic evaluation. Patients 
who needed further evaluation of the aorta due to clinical presentation and/or 
echocardiographic findings also underwent a preoperative computed tomography scan.  
Intraoperatively, the aortic valve was determined to be unicuspid (a single leaflet and 
commissure), bicuspid (two leaflets and two commissures), or tricuspid (three leaflets 
and three commissures) based on the surgeon’s inspection of the valve (Fig. 1). 
Furthermore, BAV phenotype was determined (i.e., fusion of the right and left leaflets 
with a commissural raphe, fusion of the right and non-coronary leaflets with a 
commissural raphe, fusion of the left and non-coronary leaflets with a commissural 
raphe or a true BAV without a raphe; Fig. 4). Tissue samples from the anterior part of 
the ascending aorta were collected and prepared for ribonucleic acid (RNA) isolation, 
gene array analyses, and immunohistochemistry. 
Screened 
(n = 1236) 
• Excluded (n = 429) 
• Eligible (n = 807) 
Included 
(n = 600) 
• Excluded after being 
intially included (n = 27*) 
Study 
population 
(n = 573) 
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The study population of this thesis consisted of the first 500 consecutive patients 
operated on within the setting of ASAP between February 2007 and February 2012 
(Table 7). In addition, 202 patients who were undergoing cardiac surgery (within the 
same time frame) due to aortic valve and/or ascending aortic pathology and concurrent 
coronary artery bypass grafting were included and studied retrospectively. Patients who 
were operated on between 2007 and 2009 and from whom RNA was extracted from the 
ascending aorta that was of sufficient quantity and quality for gene array analyses were 
included in Study IV (n= 109). 
 
Table 7. Study population of the thesis 
 
 Study population (n) ASAP 
Study I 300 1-300 
Study II 500 1-500 
Study III 97 1-500 
Study IV 109 Operated in 2007-2009 
Study V 702 1-500 (+202) 
 
 
 ECHOCARDIOGRAPHY 4.2
 
4.2.1 Transthoracic echocardiography 
Transthoracic echocardiography was used to preoperatively evaluate the presence and 
grade of valve pathology as well as cardiac dimensions and function in all patients. To 
assess the occurrence and grade of aortic valve stenosis, valve area, peak gradient and 
mean gradient across the valve were calculated according to the continuity- and 
Bernoulli equation. The occurrence and grade of aortic valve regurgitation was 
determined based on colour flow jet area, vena contracta, pressure half-time, jet-
density, and diastolic flow reversal in the descending aorta.  
 
4.2.2 Transesophageal echocardiography 
Perioperatively all patients were examined with transesophageal echocardiography 
when fully anaesthetised. The dimensions of the left ventricular outflow tract, annulus, 
sinus of Valsalva, sinotubular junction, ascending aorta and the root height (i.e., the 
distance between the annulus and the sinotubular junction) were measured. All 
measurements were obtained in diastole except for the diameter of the left ventricular 
outflow tract which was measured in systole. 
 
 COMPUTED TOMOGRAPHY SCANNING 4.3
Patients with suspected or confirmed dilatation of the aorta and/or aortic root were 
examined by computed tomography scanning. Maximal outer wall measurements were 
obtained in the axial plane at the annulus, sinus of Valsalva, sinotubular junction, 
ascending aorta, proximal arch, distal arch, aortic isthmus, descending aorta, suprarenal 
aorta, and infrarenal aorta (Fig. 7).  
 
 30 
Figure 7. Aortic measurement points in computed tomography scanning 
 
 
1) Annulus; 2) sinus of Valsalva; 3) sinotubular junction; 4) ascending aorta; 5) 
proximal arch, 6) distal arch, 7) aortic isthmus; 8) descending aorta; 9) suprarenal 
aorta; 10) infrarenal aorta. Reprinted with permission from Elsevier (Study III). 
 
 
 GENE EXPRESSION AND IMMUNOHISTOCHEMISTRY 4.4
RNA was isolated from the aortic tissue that was collected intraoperatively, and RNA 
was then analysed using gene arrays (an automatized method to detect expression of all 
messenger RNAs (mRNA)). A subset of the mRNAs analysed with gene arrays was 
amplified by real-time polymerase chain reaction (PCR), and then analysed to validate 
the results of the gene arrays (Study IV). Immunohistochemistry was used to visualise 
and locate protein expression in the aortic wall of the corresponding gene of interest 
(Study IV). 
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 DEFINITIONS 4.5
4.5.1 Anatomic structures 
The “aortic valve” and the “aortic root” were defined as proposed by Sievers et al. 125 
(Table 8, Fig. 8). 
 
Table 8. Definition of the aortic valve and aortic root 
 
Anatomic structure Definition 
Leaflets The moving parts that separate the left ventricle and 
the aorta 
Commissure The most distal attachment of the leaflets to the aortic 
wall 
Annulus The virtual circle formed by the nadirs of the semi-
lunar leaflet attachments 
Interleaflet triangle The area between the semi-lunar attachments of the 
leaflets from the nadir to the commissure 
Aortic valve The leaflets 
Aortic root The annulus, leaflets, leaflet attachments, interleaflet 
triangles, sinus of Valsalva and the sinotubular 
junction 
  
 
Figure 8. Definition of the aortic root and ascending aorta 
 
 
Reprinted with permission from Oxford University Press.
125
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4.5.2 BAV phenotype 
BAV phenotype was defined as a fusion of the right and left coronary leaflets with a 
commissural raphe (RL), a fusion of the right and non-coronary leaflets with a raphe 
(RN), a fusion of the left and non-coronary leaflets with a raphe (LN), or a true BAV 
without a raphe (TB) (Fig. 4).  
 
Other classifications of the various types of BAV have been proposed and differ 
somewhat from the classification used in this thesis.
126
 However, the major features of 
the most prevalent BAV phenotypes are the same: BAV-RL is identical to Sievers’ 
BAV “type 1, L-R”; BAV-RN is identical to “type 1, R-N”; BAV-LN is identical to 
“type 1, N-L” and true BAV is identical to Sievers’ ”type 0”. Sievers’ BAV “type 2” 
corresponds to what we and others have classified as a unicuspid aortic valve 
(UAV).
127, 128
 
 
4.5.3 Valve pathology 
Aortic valve stenosis was defined as when the peak gradient across the aortic valve 
exceeded 50 mm Hg and/or the mean gradient exceeded 40 mm Hg and/or the aortic 
valve area was less than 1.0 cm
2
. If the criterion for valve stenosis was met, the valve 
was classified as stenotic regardless of the presence of concomitant valve regurgitation 
since regurgitation in these instances was a consequence of valve calcification. Grade 1 
aortic valve stenosis was defined as a peak gradient across the valve of 51-64 mm Hg, 
grade 2 as 65-100 mm Hg and grade 3 as >100 mm Hg. Aortic valve regurgitation was 
graded as mild (grade 1), moderate (grade 2), moderate to severe (grade 3), and severe 
(grade 4). 
 
4.5.4 Aortic morphology 
A non-dilated aorta was defined as when the dimension of the sinus of Valsalva 
exceeded the dimension of the sinotubular junction, and the maximal aortic diameter 
did not exceed 40 mm (patients with BAV) or 45 mm (patients with TAV). An 
aneurysmatic aorta was defined as when the diameter of the sinus of Valsalva exceeded 
the diameter of the sinotubular junction, and the maximal aortic diameter exceeded 40 
mm (patients with BAV) or 45 mm (patients with TAV). An ectatic aorta was defined 
as when the dimension of the sinotubular junction exceeded the dimension of the sinus 
of Valsalva, and the maximal aortic diameter exceeded 40 mm (patients with BAV) or 
45 mm (patients with TAV). The different dilated aortic morphologies are depicted in 
Fig. 9. The descending and infrarenal aorta were deemed dilated according to the 
criteria proposed by Wanhainen et al. (i.e., the descending aorta exceeded 36 mm in 
males and 32 mm in females; the infrarenal aorta exceeded 29 mm in males and 26 mm 
in females).
129
 To attain an adequate comparison of gene expression levels between 
non-dilated and dilated aorta as well as between BAV and TAV patients in Study IV the 
aorta was considered to be non-dilated at a maximal aortic diameter of 40 mm or less 
and dilated at 45 mm or more, regardless of BAV or TAV. Patients with aortic 
diameters between 41 and 44 mm were not included in the analyses. 
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Figure 9. Dilated ascending aortas with different aortic morphologies 
 
 
a) Ascending aortic aneurysm with intact sinotubular junction and mid-ascending 
dilatation; b) aortic root aneurysm with intact sinotubular junction and no mid-
ascending dilatation; c) aortic ectasia lacking defined sinotubular junction and with 
mid-ascending dilatation. Computed tomography reconstructions, courtesy of Anders 
Svensson, Radiology Department, Karolinska University Hospital, Huddinge. 
 
 
 STATISTICAL ANALYSES 4.6
Values were presented as the mean and standard deviation (Study I-V), median and 
interquartile range (Study III-V) frequency counts, and percentages (Study I-V) and 95% 
confidence interval (Study II). Mann-Whitney U test or Student’s t test was used for 
comparisons of continuous variables. The Chi-square and Fisher’s exact test was used 
for comparisons of categorical data (Study I-V). Spearman rank correlation test was 
used for correlation analyses (Study IV). Two-way factorial analysis of variance 
(ANOVA) (Study I, II, V) and Kruskall-Wallis one-way ANOVA (Study III) were used 
for continuous variables, and logistic regression analysis were used for dichotomous 
variables (Study V). If patient characteristics were associated with the outcome 
measures, they were included in the ANOVA model in a stepwise manner. In the case 
of a significant interaction between the factors in the ANOVA model, simple main 
effects tests were examined. In Study III analysis of covariance (ANCOVA) was used 
to adjust for patient characteristics and comorbidities in comparisons between BAV and 
TAV patients. Principal components analysis based on the gene expression found in the 
gene array analysis was performed (Study IV). A p-value of less than 0.05 was 
considered statistically significant. Statistical analyses were performed using the 
Statistica 10.0 software (StatSoft® Inc, Tulsa OK, USA) and the Statview® software 
(SAS Institute Inc, version 5.0.1). 
 
 ETHICAL CONSIDERATIONS 4.7
All studies were approved by the Regional Ethical Review Board (in Stockholm) and 
informed consent was obtained from all patients. 
A B C
 34 
5 RESULTS 
 
Of 600 patients included in ASAP, 573 eventually underwent cardiac surgery within 
the setting of the study (Fig. 6). The first 500 consecutively operated patients in ASAP 
together with 202 patients with aortic valve and/or aortic pathology and in addition 
significant coronary artery disease constitute the study population of this thesis. The 
overall mean age of the patients was 66 ± 12 years (without coronary artery disease: 64 
± 12 years; with coronary artery disease: 72 ± 8 years) and the gender distribution was 
2:1 males to females (without coronary artery disease: 2:1; with coronary artery 
disease: 4:1 (p = 0.0007); without coronary artery disease: BAV 2.4:1 and TAV 1.6:1 
(p = 0.03); with coronary artery disease: BAV 7:1 and TAV 3:1 (p = 0.24)). In patients 
without coronary artery disease the surgical procedures included aortic valve 
replacement (n = 319), aortic valve plasty (n = 17) and replacement of the ascending 
aorta with a supracoronary graft with (n = 53) or without (n= 26) concurrent valve 
surgery. A composite graft was used in 60 patients and the David procedure was used 
in 25 patients. All patients with concomitant coronary artery disease underwent 
coronary artery bypass grafting in conjunction with aortic valve replacement (n = 189), 
aortic valve plasty (n = 1) or replacement of the ascending aorta with a supracoronary 
graft and concurrent valve surgery (n = 7). A composite graft was used in four patients 
and the David procedure in one patient. The distribution of valve morphology in 
relation to   indication for surgery is depicted in Fig. 10.  
 
Figure 10. Distribution of valve morphology in relation to indication for surgery 
  
 
AV – aortic valve disease; AA – ascending aortic pathology; CAD – coronary artery 
disease. 
AV AA AV + AA AV + CAD AV + AA + CAD
45%
5%
39%
9%
2%
41%
7%
8%
42%
2%
BAV TAV
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 BAV PHENOTYPE AND AORTIC MORPHOLOGY  5.1
The aim of Study I was to assess the morphology of the aortic root and ascending aorta 
in relation to valve morphology and BAV phenotype in cardiac surgery patients (n = 
300). 
 
5.1.1 General findings 
The majority of the study population had a BAV (53%) and BAV was more frequently 
associated with ascending aortic aneurysm than TAV (36% vs. 12%; p < 0.001), 
whereas ectasia was equally common in BAV and TAV patients (Fig. 11). At the time 
of surgery, BAV patients were approximately 10 years younger than TAV patients (p < 
0.0001). Aortic valve pathology (valve stenosis or regurgitation) was equally 
distributed in BAV and TAV patients when the aorta was non-dilated (p = 0.82). When 
the aorta was dilated BAV patients predominantly had aortic valve stenosis (56% vs. 
29%) while TAV patients predominantly had valve regurgitation (81% vs. 4%; p < 
0.001 for BAV vs. TAV in both instances). 
 
Figure 11. Distribution of valve morphology in relation to aortic morphology 
 
 
 
 
In BAV patients, fusion of the right and left coronary leaflets was predominant (74%) 
followed by right and non-coronary leaflet fusion (14%), and true BAV (11%; p < 
0.001). No patients had a fusion of the left and non-coronary leaflets. The distribution 
of BAV phenotypes was similar regardless of aortic morphology (p = 0.95; Fig. 12). A 
UAV was found in ten patients (3%), and four of these patients had dilatation of the 
ascending aorta. 
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Figure 12. Distribution of BAV phenotypes in relation to aortic morphology 
 
 
 
 
RL – fusion of the right and left coronary leaflets; RN – fusion of the right and non-
coronary leaflets; TB – true BAV. 
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5.1.2 Morphology of the aortic root and ascending aorta 
Regardless of aortic morphology the annulus and left ventricular outflow tract were 
always larger in BAV patients than in TAV patients (p < 0.001; Table 9). BAV patients 
had smaller dimension of the ascending aorta when the aorta was ectatic than TAV 
patients (50 ± 7 vs. 56 ± 9 mm, p = 0.005). There were minor but statistically 
significant differences in aortic dimensions associated with BAV phenotype (Table 10).  
 
Table 9. Aortic dimensions in relation to valve and aortic morphology 
 
 BAV TAV 
 N A E N A E 
Annulus  24 ± 4 25 ± 4 27 ± 2 23 ± 3 23 ± 5 23 ± 3 
LVOT 25 ± 4 26 ± 4 27 ± 2 23 ± 3 24 ± 4 25 ± 3 
A – aneurysm; E – ectasia; LVOT – left ventricular outflow tract; N – non-dilated 
aorta. Aortic dimensions are presented in millimetres and as mean ± SD.  
 
 
Table 10. Differences in aortic dimensions associated with BAV phenotype  
  
Aortic morphology and measure points Statistics 
Aortic root height in non-dilated  or aneurysmatic 
aorta 
(RL and RN < TB); p ≤ 0.01 
Sinotubular junction and sinus of Valsalva in 
aneurysmatic aorta 
(RL < TB); p = 0.02 
Maximal aortic diameter in ectatic aorta (RL and RN > TB); p ≤ 0.01 
RL – fusion of the right and left coronary leaflets; RN – fusion of the right and non-
coronary leaflets; TB – true BAV. 
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 VALVE PATHOLOGY AND AORTIC MORPHOLOGY 5.2
The aim of Study II was to investigate a possible association between the severity of 
valve pathology and the morphology of the aortic root and ascending aorta (n = 500). 
 
5.2.1 General findings 
The majority of patients had a BAV (55%), and 42% of BAV patients and 15% of TAV 
patients had an ascending aortic aneurysm. Thus, an ascending aortic aneurysm was 
approximately three times more common in BAV patients than in TAV patients (p < 
0.0001), whereas ectasia was equally common in BAV and TAV patients (p = 0.40) 
undergoing cardiac surgery. The distribution of valve pathology was similar in BAV 
and TAV patients when the aorta was non-dilated (p ≥ 0.42), whereas aortic valve 
stenosis was more common in the BAV group than in the TAV group when the aorta 
was aneurysmatic or ectatic (p ≤ 0.04). Conversely, valve regurgitation was more 
common in TAV patients than BAV patients when the aorta was dilated (p ≤ 0.008; 
Fig. 13).  
 
Figure 13. Distribution of valve pathology in relation to aortic morphology 
 
 
 
 
The relative distribution of the different grades of valve pathology did not differ 
between TAV and BAV patients (Table 11) and there was no difference in left 
ventricular function (i.e., ejection fraction) between the groups (p ≥ 0.24). BAV 
patients were younger than TAV patients when the aorta was non-dilated (~10 years, p 
< 0.0001) or aneurysmatic (~5 years, p = 0.02).  
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Table 11. Distribution of valve pathology in relation to valve morphology and BAV 
phenotype 
 
 BAV (n = 249) TAV (n = 192) 
 All 
(n = 249) 
RL 
(n = 184) 
RN 
(n = 38) 
TB 
(n = 25) 
 
AS1 15% 14% 18% 16% 8% 
AS2 43% 46% 37% 32% 39% 
AS3 12% 10% 13% 20% 10% 
AR1-2 13% 13% 16% 12% 15% 
AR3-4 17% 17% 16% 20% 28% 
AS – aortic valve stenosis; AR – aortic valve regurgitation. For definition of grade of 
valve pathology see section 4.5.3. 
 
 
5.2.2 Aortic dimensions in relation to valve pathology 
In general, when the aorta was non-dilated, aortic dimensions were larger when valve 
regurgitation was present than when valve stenosis was present, and this was true of 
both BAV and TAV patients (p ≤ 0.03). In BAV patients with an aneurysm, the 
sinotubular junction, annulus, and left ventricular outflow tract were larger when valve 
regurgitation was present than when valve stenosis was present (p ≤ 0.003). There were 
no differences in the dimensions of ectatic aortas in relation to valve pathology in BAV 
patients. Notably only two TAV patients had a combination of aortic aneurysm or 
ectasia and valve stenosis, while this was seen in 76 BAV patients (Fig. 13). 
 
5.2.3 Severity of valve pathology and non-dilated aorta 
In both BAV and TAV patients with a non-dilated aorta, the general pattern was that 
increasing severity of valve pathology was associated with smaller dimensions of the 
aortic root and ascending aorta (Fig. 14). However, in both BAV and TAV patients 
with valve regurgitation and in TAV patients with valve stenosis, the annulus and left 
ventricular outflow tract were larger with increasing severity of valve pathology. 
 
5.2.4 Severity valve pathology and dilated aorta 
In BAV patients with valve stenosis and aortic aneurysm the general pattern of 
increasing grade of valve pathology being associated with smaller aortic dimensions 
was still evident (Fig. 15). This pattern was also found in both BAV and TAV patients 
with aortic aneurysm and valve regurgitation at the ascending aorta whereas the 
measurement points of the aortic root were larger with increasing severity of 
regurgitation.  
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Figure 14. Grade of valve pathology in relation to aortic dimensions in non-dilated 
aorta 
 
 
AS – aortic valve stenosis; AR – aortic valve regurgitation. See section 4.5.3. for 
definition of grade of valve pathology. p < 0.05 for TAV patients with AS at the annulus 
and for both BAV and TAV patients with AR at the ascending aorta.  
 
Figure 15. Grade of valve pathology in relation to aortic dimensions in aneurysmatic 
aorta 
 
 
p < 0.05 for BAV patients with AS at the annulus and p < 0.0001 for both BAV and 
TAV patients with AR at the annulus and ascending aorta. See Fig. 14 for 
abbreviations. 
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 DIMENSIONS OF THE DISTAL AORTA 5.3
The aim of Study III was to evaluate a possible correlation between ascending aortic 
dilatation and dilatation of the remaining aorta in patients with BAV or TAV that were 
undergoing surgery due to ascending aortic dilatation (n = 97).  
 
5.3.1 General findings 
In total, 64% of the patients had a BAV and 36% had a TAV. All patients underwent 
replacement of the ascending aorta due to aortic dilatation; the maximal aortic diameter 
was 52 (0.4) mm in BAV patients and 53 (0.8) mm in TAV patients (values are given 
as median and interquartile range). With the exception of the distribution of valve 
pathology, the characteristics of BAV and TAV patients did not differ. In the BAV 
group, 34% of patients had aortic valve stenosis and 45% of patients had valve 
regurgitation, whereas in the TAV group, no patients had valve stenosis and, 83% had 
valve regurgitation. Of the BAV patients, 77% had a RL configuration, 13% had a RN 
configuration, and 10% had a true BAV.  
 
5.3.2 Arch, descending, and abdominal aortic dimensions 
There were no differences between BAV and TAV patients in diameters at the annulus, 
sinus of Valsalva, sinotubular junction, or ascending aorta. By contrast, the dimensions 
of the proximal arch, distal arch, aortic isthmus, descending aorta, suprarenal aorta, and 
infrarenal aorta were consistently smaller in BAV patients than in TAV patients (p < 
0.001). 
5.3.3 BAV phenotype, valve pathology, and the distal aorta 
In BAV patients, there were no differences in aortic dimensions related to functional 
status of the valve or BAV phenotype. TAV patients with valve regurgitation had larger 
aortic dimensions (indexed to body surface area) at the level of the sinus of Valsalva, 
sinotubular junction, and distal arch compared with TAV patients without valve 
pathology (p ≤ 0.03). 
 
5.3.4 Concomitant dilatation of the distal aorta 
Concomitant dilatation of the descending aorta was more common in TAV patients 
than in BAV patients (37% vs. 5%; p < 0.001). Dilatation of the infrarenal aorta alone 
(five BAV patients, three TAV patients) or in combination with dilatation of the 
descending aorta (one BAV patient, two TAV patients) was equally common in both 
groups (p > 0.2). 
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 PROTEASES IN THE AORTIC WALL 5.4
The aim of Study IV was to analyse the occurrence of MMPs and TIMPs in the aortic 
media of patients with BAV or TAV (n = 109). 
 
5.4.1 MMP and TIMP expression in the aortic wall 
In general, mRNA expression of gelatinases (MMP2 and MMP9), stromelysin 3 
(MMP11), all membrane-bound MMPs (MMP14, -15, -16, -17, -24, and -25), MMP19, 
MMP21, MMP28, and TIMP1-4 was detected in both the intima/media section and the 
adventitia section of the aortic wall. The expression pattern was seen in both non-
dilated and dilated aortas and in both BAV and TAV patients. However, the 
collagenases (MMP1, -8, and -13) were not detected at levels above background 
expression.  
 
5.4.2 Protease expression and aortic morphology  
A principal component analysis of the MMPs and TIMPs expressed in the intima/media 
section of the ascending aorta revealed a separation of TAV patients with non-dilated 
aortas from TAV patients with dilated aortas (Fig. 16). By contrast, no separation was 
detected when analysing the BAV group separately or when analysing BAV and TAV 
patients together. Thus, differences in MMP and TIMP expression between non-dilated 
and dilated aortas seem to mainly be found in TAV patients. The MMPs and TIMPs 
responsible for the separation of non-dilated aortas from dilated aortas in TAV patients 
are in the lower right quadrant of the loading plot in Fig. 17. No differences between 
the groups were found when analysing the adventitia section of the aorta. 
 
Figure 16. Principal component analysis of gene expression of MMPs and TIMPs in 
TAV patients with non-dilated (black) and dilated (red) aortas 
 
 
Reprinted with permission from Elsevier (Study IV).  
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Figure 17. Score and loading plot of the principal component analysis of gene 
expression of MMPs and TIMPs in TAV patients with non-dilated (black) and dilated 
(red) aortas 
 
 
Reprinted with permission from Elsevier (Study IV). 
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Univariate analyses showed no differences in the levels of mRNA expression between 
BAV and TAV patients with non-dilated aortas. In both BAV and TAV patients, 
expression levels of MMP14, MMP19, and TIMP2 were higher in the intima/media 
section of dilated aortas than in non-dilated aortas. In TAV patients, expression levels 
of MMP17, MMP21, MMP25, MMP28, and TIMP4 were all lower in dilated aortas 
than in non-dilated aortas. In BAV patients, the expression levels of none of the MMPs 
or TIMPs were lower in dilated vs. non-dilated aortas.  
 
Correlation analyses of MMP expression levels in the intima/media section and the 
maximal ascending aortic diameter in TAV patients was performed. Of the MMPs that 
showed higher expression levels in TAV patients with dilated aortas, MMP19 
correlated positively with maximal aortic diameter (Rho 0.61, p = 0.004 and Rho 0.57, 
p = 0.008 for raw values and values indexed to body surface area, respectively). 
MMP14 showed borderline significance for raw values (Rho 0.40, p = 0.06) but did not 
correlate with values indexed to body surface area (Rho 0.12, p > 0.2). Of the MMPs 
and TIMPs that showed lower expression levels in TAV patients with dilated aortas, 
TIMP4 correlated negatively with raw values (Rho -0.49, p = 0.02), whereas MMP25, 
MMP28, and TIMP4 correlated negatively with values indexed to body surface area 
(Rho -0.45, p = 0.04; Rho -0.43, p < 0.05; and Rho -0.55, p = 0.01, respectively). No 
other significant correlations between MMP/TIMP expression and maximal aortic 
diameter were found. 
 
5.4.1 MMP14 and MMP19 protein expression in TAV patients 
Immunohistochemistry analysis showed that protein expression of MMP19 was mainly 
seen in endothelial cells of TAV patients with non-dilated aortas. In dilated aortas 
endothelial expression MMP19 was still present but strong MMP19 expression was 
also evident in the medial layer. Similar to MMP19, MMP14 protein expression was 
upregulated in the media of dilated aortas.  
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 CLINICAL CHARACTERISTICS AND CORONARY ARTERY 5.5
DISEASE  
The aim of Study V was to evaluate patients characteristics in relation to valve 
morphology, valve pathology, aortic morphology and coronary artery disease (n = 702). 
 
5.5.1 Patient characteristics 
Distribution of valve morphology, valve pathology, and aortic morphology in patients 
without coronary disease (n = 500) is described in section 5.2.1 (Study II). In patients 
with coronary artery disease (n = 202), 16% had a BAV, 84% had a TAV, 94% had 
isolated aortic valve pathology, and 6% had concomitant ascending aortic dilatation. 
Distribution of valve, aortic, and coronary artery pathology in relation to valve 
morphology is depicted in Fig. 18. Aortic valve stenosis was the dominating valve 
pathology in both BAV and TAV patients when the aorta was non-dilated (Fig. 19; p = 
0.13). Patients with coronary artery disease were older than those without, regardless of 
valve morphology. Without coronary artery disease, male gender was more common in 
TAV patients with valve and aortic pathology than in TAV patients with isolated valve 
pathology (p < 0.001). The male to female ratio in patients with coronary artery disease 
was 3.8:1 and was notably higher than in patients without coronary artery disease (2:1).  
 
Figure 18. Distribution of valve, aortic and coronary artery pathology in relation to 
valve morphology 
 
 
AV- aortic valve disease; AA – ascending aortic pathology; CAD – coronary artery 
disease. 
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Figure 19. Distribution of valve and aortic pathology in BAV and TAV patients with or 
without coronary artery disease 
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5.5.2 Echocardiographic findings 
The aortic valve peak gradient was approximately 7 mm higher and the left ventricular 
end-systolic diameter was approximately 14 mm larger in TAV patients with coronary 
artery disease and isolated valve pathology than in patients without coronary artery 
disease (p ≤ 0.04). In both BAV and TAV patients with isolated valve pathology, the 
ejection fraction was approximately 9% lower when coronary artery disease was 
present than when it was absent (p ≤ 0.003). This was also observed in BAV patients 
with concomitant aortic dilatation (p ≤ 0.02). Both BAV and TAV patients with 
coronary artery disease and isolated valve pathology had larger dimension of the 
ascending aorta than patients without coronary disease (~2-5 mm; p < 0.0001). This 
was also apparent in BAV patients with dilated aortas (~7 mm; p = 0.02). 
 
5.5.3 Medical history 
TAV patients without coronary artery disease and with isolated valve pathology were 
more likely to have diabetes (14% vs. 6%) and relatives with valve pathology (16% vs. 
3%) than TAV patients with concomitant aortic dilatation (p ≤ 0.04). TAV patients 
with coronary artery disease and valve pathology were less likely to have relatives with 
cerebrovascular lesions than TAV patients with aortic dilatation (13% vs. 57%; p = 
0.01). Both BAV and TAV patients with coronary artery disease and valve pathology 
had a higher frequency of hypertension (BAV: 85% vs. 48%; TAV 88% vs. 65%) and 
more relatives who died suddenly (BAV: 32% vs. 14%; TAV 26% vs. 8%) than those 
without coronary artery disease (p ≤ 0.04).  
 
5.5.4 Medical treatment 
TAV patients with isolated valve pathology but without coronary artery disease had a 
higher intake of lipid-lowering agents and calcium inhibitors than TAV patients with 
aortic dilatation (51% vs. 20% and 23% vs. 7%, respectively; p ≤ 0.03). BAV patients 
with coronary artery disease and isolated valve pathology had a higher intake of lipid-
lowering agents than patients with aortic dilatation (19% vs. 60%; p = 0.02). The 
corresponding group of TAV patients had a lower intake of angiotensin converting 
enzyme inhibitors (28% vs. 71%; p = 0.03). BAV patients with coronary artery disease 
and isolated valve pathology had a higher intake of beta blockers (73% vs. 41%), 
acetylsalicylic acid (81% vs. 31%), lipid-lowering agents (81% vs. 35%), thiazide 
diuretics (27% vs. 8%) and long-acting nitrates (73% vs. 41%) than BAV patients 
without coronary artery disease (p ≤ 0.02). TAV patients with coronary artery disease 
had a higher intake of beta blockers (67% vs. 48%), acetylsalicylic acid (68% vs. 45%), 
lipid-lowering agents (78% vs. 51%), insulin (21% vs. 5%) and long-acting nitrates 
(67% vs. 48%; p ≤ 0.007) than TAV patients without coronary artery disease.  
 
5.5.5 Laboratory findings 
BAV patients with coronary artery disease and isolated valve pathology had slightly 
higher levels of creatinine and C-reactive protein than BAV patients without coronary 
artery disease (p ≤ 0.03).  
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6 DISCUSSION 
 
 CLINICAL CHARACTERISTICS 6.1
A consistent finding in the studies of this thesis was that more than 50% of patients 
who underwent cardiac surgery due to valve and/or aortic pathology had a BAV (Study 
I-V). Furthermore, in this population of cardiac surgery patients an ascending aortic 
aneurysm was approximately three times more common in BAV patients than in TAV 
patients. This finding confirms previous reports of aortic dilatation being substantially 
more common in BAV patients.
2
 Thus, in both surgical and non-surgical patients, BAV 
is highly associated with ascending aortic dilatation. However, in patients with 
coronary artery disease, BAV was relatively rare (BAV, 16%; TAV, 84%) (Study V). 
Furthermore, in both BAV and TAV patients with the combination of valve pathology 
and coronary artery disease, ascending aortic dilatation was remarkably uncommon. 
The distribution of valve pathology was similar in BAV and TAV patients when the 
aorta was non-dilated. By contrast, in patients with an ascending aortic aneurysm, valve 
stenosis was the dominating valve pathology in BAV patients, whereas TAV patients 
rarely had a combination of valve stenosis and dilatation of the aortic root and/or 
ascending aorta. In both BAV and TAV patients with coronary artery disease, the 
predominant valve pathology was valve stenosis. BAV patients are usually referred to 
as being approximately 10 years younger than TAV patients at the time of cardiac 
surgery, which was consistent with our findings in patients with non-dilated aortas 
(Study I, II, IV, V).
130
 In patients with ascending aortic aneurysm or coronary artery 
disease, this age difference was smaller but still significant (Study II, III, V). In general, 
a male to female ratio of 2:1 was found in both BAV and TAV patients, and this ratio 
increased in patients with ectasia of the aorta or coronary artery disease (Study I, II, V).  
 
The finding that coronary artery disease was rare in BAV patients but was associated 
with TAV, advanced age, and male gender (Study V) is in agreement with previous 
work.
130, 131
 Risk factors of cardiovascular disease or the manifestations of  
cardiovascular disease were more common in both BAV and TAV patients with 
coronary artery disease (BAV and TAV patients: larger ascending aorta, higher 
frequency of hypertension, more relatives who died suddenly, and a higher intake of 
drugs used to treat cardiovascular disease; TAV patients: advanced age, male gender, 
more severe valve stenosis, larger ventricular dimensions, and reduced ejection 
fraction) than in patients without. Age, coronary artery disease, and concomitant 
coronary artery bypass grafting were suggested to be predictors of mortality in patients 
undergoing aortic valve surgery, although the distinction between BAV and TAV was 
not made.
132
 In this thesis, the combination of valve pathology and coronary artery 
disease was mainly found in TAV patients. This finding suggests that valve 
morphology might be associated with differences in outcome in patients undergoing 
isolated valve surgery in comparison with patients undergoing valve surgery and 
concomitant coronary artery bypass grafting. Interestingly, work by Roberts et al. 
found that patients with UAV or BAV have a greater probability of survival than TAV 
patients when undergoing aortic valve replacement with or without concurrent coronary 
artery bypass grafting. However, no difference in long-term survival related to surgical 
procedure was found. It is from these results possible to hypothesise that valve 
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morphology rather than surgical procedure (i.e., concomitant coronary artery bypass 
grafting) affects the probability of survival.
131
 
 
The distribution of valve pathology, medical history, medication, and laboratory 
findings was similar in BAV and TAV patients with coronary artery disease. By 
contrast, in the group of patients without coronary artery disease and with isolated 
valve pathology, TAV patients were older, more frequently had hypertension and 
previous cerebrovascular lesions, had a higher intake of cardiovascular drugs, and had 
higher creatinine levels than BAV patients. This finding supports the notion that valve 
morphology is possibly linked to outcome in patients undergoing cardiac surgery; TAV 
patients seem to have higher cardiovascular risk than BAV patients, even without the 
presence of coronary artery disease. In accord, the relative distribution of BAV 
decreased substantially in patients with coronary artery disease (Study V). 
 
Atherosclerosis and inflammation are important factors in the development of coronary 
artery disease and aortic valve stenosis.
133, 134
 To what extent inflammation and 
atherosclerosis contributes to aneurysm formation differs with aortic location and is 
thought to be less important in the ascending aorta than the descending and abdominal 
aorta.
98, 99
 Furthermore, coronary artery disease is a common finding in patients 
undergoing endovascular or surgical repair of descending, thoracoabdominal or 
abdominal aortic aneurysms.
135, 136
 Aneurysm formation of the ascending aorta is 
associated with inflammation and immune response in TAV patients, but not in BAV 
patients.
100
 Interestingly, aortic valve stenosis was rarely found in TAV patients with 
dilated aortas (Study I, II, III, V). Furthermore, in both BAV and TAV patients, 
ascending aortic dilatation was uncommon when coronary artery disease was present 
which is in agreement with previous findings in BAV patients.
137
 In spite of an 
association between inflammation and aneurysm formation in TAV patients, the 
combination of valve stenosis, coronary artery disease, and aortic dilatation was rare in 
TAV patients. BAV is frequently associated with ascending aortic dilatation, which in 
turn is rarely associated with coronary artery disease. Thus, valve morphology may 
influence the development of coronary artery disease. 
 
 
 BAV PHENOTYPE AND AORTIC MORPHOLOGY 6.2
BAV phenotype has been suggested to be related to aortic morphology and to several 
aspects of BAV disease. Novaro et al. reported a statistically significant correlation 
between the RL configuration and aortic valve regurgitation. In addition, a correlation 
was found between the RN configuration and larger dimensions of the ascending aorta 
and the presence of aortic stenosis, although none of these findings were statistically 
significant.
138
 Fernandes et al. showed a relation between the severity of valve 
pathology (both stenosis and regurgitation) and BAV with a RN configuration.
79
 
Moreover, an association of BAV-RL and coarctation was demonstrated. A larger 
diameter of the sinus of Valsalva and a smaller diameter of the aortic arch has been 
associated with the RL configuration.
139
 The authors also reported that the elastic 
properties of the aorta differed according to BAV phenotype where BAV-RL showed a 
higher stiffness index and a lower distensibility at the sinus of Valsalva. Russo et al. 
could not confirm a relation between BAV phenotype and the distribution of valve 
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pathology but found that patients with BAV-RL had larger dimensions of the sinus of 
Valsalva and more pronounced medial degeneration.
93
 In patients with mild to 
moderate aortic valve stenosis, an association of BAV-RL with larger dimensions of 
the annulus and the sinus of Valsalva has been reported 
140
 which supports the results of 
Russo et al. and Schaefer et al. Ikonomidis et al. showed that BAV patients with dilated 
aortas have an increased global activity of MMPs in comparison with controls (i.e., 
normal valve and non-dilated aorta).
141
 Furthermore, the authors reported differences in 
MMP activity related to BAV phenotype.  
 
The relative distribution of BAV phenotypes observed in this thesis is similar to those 
previously reported.
104, 139, 142, 143
 Thus, in general 60-85% of BAV patients have BAV-
RL, while BAV-RN is less common and is found in approximately 15-40% of patients 
with BAV. A true BAV is found in about 10% of BAV patients, whereas fusion of the 
left and non-coronary leaflets is virtually non-existent. BAV patients had larger 
dimensions of the annulus and left ventricular outflow tract than TAV patients 
regardless of aortic morphology (i.e., non-dilated, aneurysm, and ectasia), valve 
pathology, and severity of valve pathology (Study I, II). In contrast to previous work, a 
relationship was not established between BAV phenotype and the frequency of 
aneurysm or ectasia.
93, 139, 140
 In addition, only minor differences in aortic dimensions 
related to BAV phenotype were shown and an association between BAV phenotype 
and the distribution of valve pathology could not be demonstrated (Study I, II), which is 
in contrast to the findings of Novaro et al.
138
 The findings of Study I and Study II were 
further confirmed in Study III where neither BAV phenotype nor valve pathology 
influenced the aortic dimensions. Taken together, the relative influence of BAV 
phenotype on aortic morphology seems to be of minor importance in patients 
undergoing cardiac surgery, which is in agreement with the work of Cecconi et al.
144
 
This implies that differences in the blood flow pattern across the aortic valve related to 
BAV phenotype, aortic wall shear stress, and pressure distribution do not solely explain 
the increased prevalence of ascending aortic dilatation in BAV patients. 
 
 
 VALVE PATHOLOGY AND AORTIC MORPHOLOGY 6.3
Aortic valve stenosis and valve regurgitation were equally distributed when the aorta 
was non-dilated (Study I); however, when the aorta was dilated, valve stenosis was 
more common in the BAV group and valve regurgitation was more common in the 
TAV group. Study II confirmed these findings and further emphasised that the 
combination of a TAV, valve stenosis, and dilatation of the ascending aorta is rare 
(only 2 out of 212 TAV patients). As suggested by others 
1, 145, 146
 and substantiated by 
our findings, the term “post-stenotic dilatation” seems to be appropriate only in BAV 
patients as aortic dilatation was rarely associated with aortic valve stenosis in TAV 
patients but was frequently seen in BAV patients with valve stenosis. It is also 
important to recognise that not all BAV patients with aortic valve stenosis have a 
dilated aorta, and that patients with dilated ascending aortas may have a well-
functioning non-calcified BAV.
46, 147, 148
 In Study I, 6% of BAV patients and 4% of 
TAV patients in had dilated aortas without any concomitant aortic valve pathology. 
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In general, and apparent in both BAV and TAV patients, aortic dimensions were larger 
in patients with valve regurgitation than in those with valve stenosis, and increasing 
severity of valve pathology was associated with smaller aortic dimensions. It has been 
suggested that a functionally normal BAV (i.e., not deemed calcified, stenotic, or 
regurgitant by standard echocardiographic definitions) is stenotic due to its inborn 
constitution and thereby causes turbulent flow across the valve to a greater extent than 
TAV.
60
 Differences in aortic flow patterns related to BAV phenotype have been 
demonstrated.
116
 It has been proposed that aortic wall shear stress is more pronounced 
in BAV patients than in TAV patients and in addition related to aortic valve area.
149
 
BAV patients have accelerated progression of aortic valve calcification, which leads to 
hemodynamically and clinically significant valve stenosis earlier in life compared with 
TAV patients.
51, 57-59
 It has been suggested that the severity of valve pathology 
positively correlates with aortic root and ascending aortic dimensions.
150
 However, the 
results of Study II demonstrated an inverse effect of the severity of valve pathology on 
aortic diameters, where increasing severity of valve pathology was associated with 
smaller aortic dimensions, which is in agreement with the work of Novaro et al.
138
 This 
pattern was present in both BAV patients (both non-dilated and dilated aorta) and TAV 
patients (non-dilated aorta) with aortic valve stenosis.  
 
Previous studies on the relationship between the severity of valve regurgitation and 
aortic dimensions have mainly shown that an association exists and that the aortic 
dilatation is predominantly located at the sinus of Valsalva.
138, 150, 151
 Our findings 
corroborate the majority of the previous results (Study II) and the few discrepancies 
noted might be related to differences in the study group composition such as whether 
stratification according to valve and aortic morphology was performed.   
 
There are differences in the underlying pathological mechanisms of aneurysm 
formation that are related to aortic location (i.e., ascending, descending, and abdominal) 
and to valve morphology. Impaired elastic properties of the aortic wall have been 
shown to be present in BAV individuals.
104, 152
 Increased stiffness and reduced 
distensibility of the aortic wall has been found in both children and adults with BAV, 
although it is not causatively related to aortic dilatation.
104, 152
 Whether reduced 
elasticity and increased stiffness of the aorta explains the association between 
increasing grade of valve stenosis and smaller dimensions of the ascending aorta is not 
known.  
 
In the absence of serial measurements of aortic dimensions, it may be hypothesised that 
patients with a small aortic annulus at baseline are prone to develop more severe aortic 
valve stenosis than patients with larger aortas. It could also be argued that this would be 
even more pronounced in BAV patients than TAV patients due to an increased 
turbulent flow across the valve, thereby explaining the findings of an association 
between the severity of valve stenosis and smaller aortic size. However, BAV patients 
have larger dimensions of the annulus and left ventricular outflow tract than TAV 
patients, regardless of aortic morphology (i.e., non-dilated or dilated aorta) (Study I, II). 
Furthermore, the hypothesis is contradicted by the finding that, in TAV patients with 
non-dilated aorta, increasing severity of valve stenosis was associated with larger 
diameters of the left ventricular outflow tract and annulus despite these measurement 
points being smaller in TAV patients than in BAV patients irrespective of the grade of 
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valve stenosis. Moreover, the association between increasing severity of valve 
pathology and smaller aortic dimensions was found in both non-dilated and dilated 
aortas. Thus, these findings do not support the suggestion that altered hemodynamics is 
the dominating factor responsible for the increased prevalence of ascending aortic 
dilatation in BAV patients. Based on the suggestion that a functionally normal BAV is 
in fact “stenotic” and therefore the cause of turbulent flow and increased wall shear 
stress in concert with the premature valve calcification seen in BAV, differences in 
aortic morphology between BAV and TAV patients related to the severity of valve 
pathology would be expected. However, the pattern of changes in aortic dimensions 
related to the severity of valve pathology is strikingly similar in the two groups (Study 
II). Furthermore, if higher grades of valve stenosis create a clinically significant 
increase in aortic wall shear stress, TAV patients with aortic valve stenosis should 
develop ascending aortic aneurysm; however this is, at least in a surgical population, 
virtually non-existent. It is however arguable that a BAV is subjected to a life-time of 
hemodynamic stress whereas a stenotic TAV develops valvular lesions responsible for 
aberrant flow patterns only later in life, still not all BAV patients develop aortic 
dilatation. 
 
 
 DIMENSIONS OF THE DISTAL AORTA 6.4
BAV patients with dilated ascending aortas consistently had smaller arch, descending, 
suprarenal, and infrarenal aortic dimensions than TAV patients (Study III). All patients 
studied underwent replacement of the ascending aorta, and BAV and TAV patients 
were comparable with regard to ascending aortic dimensions at the time of surgery. 
Differences in clinical characteristics and comorbidities were statistically corrected for, 
and neither valve pathology nor BAV phenotype influenced the aortic dimensions in 
BAV patients. Thus, the difference in dimensions of the distal aorta could not be 
attributed to these factors. Concomitant dilatation of the descending aorta was more 
common in TAV patients than in BAV patients, and this suggests that BAV-associated 
aortic dilatation is mainly confined to the aortic root and/or ascending aorta. By 
contrast, TAV-associated aortic dilatation can be present in all aortic segments. 
 
The association between ascending aortic dilatation and smaller dimensions of the 
remaining aorta in BAV patients is in agreement with previous findings.
144
 However, 
the results differ from those of Fazel et al. who reported that 28% of BAV patients with 
a dilated ascending aorta had concomitant dilatation of the transverse arch.
153
 This 
discrepancy might be explained by differences in the definition of aortic measurement 
points and analytical methods between the studies. Alegret et al. reported an increased 
prevalence of concomitant dilatation of the abdominal aorta in TAV patients older than 
60 years and who have dilatation of the sinus of Valsalva.
154
 Conversely, patients with 
abdominal aortic aneurysm have been reported to have a high prevalence of 
concomitant dilatation of the descending aorta but the distinction between BAV and 
TAV was not made.
155
 
 
 
   53 
 AORTIC WALL DEGENERATION 6.5
The mRNA expression of all known members of the MMP family and their 
endogenous inhibitors, TIMPs, in the ascending aortic wall was analysed with reference 
to valve and aortic morphology (Study IV). The results of principal components 
analysis based on the genes found to be expressed above the set threshold suggested 
that differences in gene expression between non-dilated and dilated aortas are 
predominately found in TAV patients. MMP19 expression was positively correlated 
with aortic diameter in TAV patients, but not in BAV patients, and correlation analysis 
of MMP14 expression and aortic diameter showed borderline significance. Thus, 
MMP14 and MMP19 were identified as proteolytic enzymes that are potentially 
involved in the pathogenesis of ascending aortic dilatation in TAV patients.  
 
The results support previous findings that there are differences in molecular 
mechanisms responsible for aneurysm formation that are related to both aortic location 
(i.e., ascending, descending, abdominal) 
94, 95
 and valve morphology (BAV/TAV).
156, 157
 
In both non-dilated and dilated ascending aortas, regardless of valve morphology, gene 
expression of gelatinases, MMP11, all membrane bound MMPs, MMP19, MMP21, 
and MMP28 was found. This MMP expression profile differs from that in the 
abdominal aorta, where MMP1, -2, -3, -8, -9, -12, -13, and -14 are suggested to affect 
aneurysm formation.
158
 
 
In the multivariate analysis, there were no differences in mRNA expression between 
BAV and TAV patients with non-dilated aortas. Furthermore, analysing BAV and TAV 
patients separately, differences related to aortic morphology was mainly found in the 
TAV group. Univariate analyses of gene expression in relation to aortic morphology 
revealed that MMP14, MMP19, and TIMP2 were upregulated in dilated aortas 
compared with non-dilated aortas in both BAV and TAV patients. A downregulation of 
gene expression was only found in the TAV group (MMP17, MMP21, MMP25, 
MMP28, and TIMP4). Correlation analysis of MMP14, MMP19, and TIMP2 gene 
expression with maximal aortic diameter showed a strong positive correlation of 
MMP19 with maximal aortic diameter; however this was only in TAV patients. The 
principal components analysis showed a separation of non-dilated aortas from dilated 
aortas only in the TAV group, which corroborates the results of the univariate analysis 
and the correlation analysis. Taken together, these findings suggest that MMP and 
TIMP gene expression profiles are likely to affect aneurysm formation in TAV patients, 
but not in BAV patients. 
 
MMP19 can hydrolyse several matrix components such as collagen IV, laminin, 
nidogen, tenascin, fibronectin and gelatin 
159
 and MMP19 is expressed in various non-
diseased tissues but not found in leukocytes.
160
 Previous reports of MMP19 expression 
in the endothelium, medial layer, and smooth muscle cells of blood vessels are in 
accord with our findings.
161, 162
 
 
MMP14 is membrane bound and in its substrate specificity similar to the MMPs 
implicated in abdominal aortic aneurysm formation (i.e., the collagenases, matrilysins 
and stromelysins), and is in this context considered to promote the invasion of 
inflammatory cells into the aortic wall.
158, 163
 However, similar to MMP19 the MMP14 
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protein expression was mainly upregulated in the medial layer of the dilated aorta as 
shown by the immunohistochemical analysis. This region consists mainly of smooth 
muscle cells and myofibroblasts but only a few inflammatory cells. MMP14 has been 
suggested to be involved in the activation of proMMP2 via complex binding to 
TIMP2.
164
 TIMP2 was found to have higher expression levels in dilated aortas in both 
BAV and TAV patients. However, TIMP2 expression did not contribute to the 
separation of non-dilated from dilated aortas in the principal components analysis and 
further did not correlate to maximal aortic diameter.  
 
There are previous reports of MMP1, -8, -13 (collagenases) and MMP7 protein 
expression in aneurysms of the ascending aorta.
108
  Moreover, MMP3 and MMP7 have 
been shown to be retained in areas of mucoid degeneration in the ascending aorta of 
patients with various aortic pathologies and aetiologies.
85
 Increased levels of MMP1 
and MMP9 protein expression in patients with thoracic aortic aneurysm have also been 
demonstrated.
165
 However, the distinction between the ascending and the descending 
aorta was not made and the aortic pathologies included aneurysms, intramural 
hematomas, and aortic dissections. 
 
There are several possible explanations for the diverging results. Differences in study 
population composition (i.e., aetiology, aortic pathology, and aortic section studied) 
make a direct comparison between the studies difficult. It is possible that the exon array 
used in this thesis was not sensitive enough, however the results from the exon array 
analysis were confirmed by real-time PCR. The medial and adventitial layer were 
analysed separately based on the hypothesis that the inflammatory profiles of the layers 
differ. However, the same MMPs were expressed above background in both layers. It is 
important to remember that gene expression does not always mirror protein expression 
or enzymatic activity, and that local expression cannot be excluded when analysing 
large tissue samples (i.e., dilated aortic specimens). It is also possible that proteins 
found in the aortic wall are not synthesised locally and the finding a result of 
entrapment of circulating proteases within the aortic wall. 
 
The relevance of the decreased MMP17, -21, -25, and -28 expression in TAV patients 
with dilated aortas is not known. The downregulation of these MMPs may represent a 
marker of de-differentiation of smooth muscle cells and fibroblasts and/or smooth 
muscle cell or myofibroblast apoptosis. MMP21 and MMP25 are structurally similar 
and found in various tissues and in cells such as fibroblasts and inflammatory cells.
166, 
167
 Decreased MMP21 expression has been suggested to be a marker of de-
differentiated tumour cells 
168
 and MMP28 is downregulated in malignant tumours.
169
 It 
is also plausible that these proteases have a role in apoptosis that is highly associated 
with aneurysm formation.
170
 MMP21 expression is not associated with apoptosis in 
tumour cells,
171
 and the potential role of MMP21, -25 and -28 in ascending aortic 
aneurysm formation needs to be analysed further.  
 
 
 BAV-ASSOCIATED AORTOPATHY 6.6
In view of the apparent differences in morphology and opening shape between a non-
diseased BAV and a non-diseased TAV 
60
 and how gravely valve stenosis can alter the 
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morphology and function of an aortic valve it is reasonable to adhere to the 
hemodynamic theory of BAV-associated aortic dilatation. Indeed, differences in 
transvalvular flow have been demonstrated between BAV and TAV patients.
172
 Aortic 
wall shear stress, i.e., the force of friction between the blood and the endothelial cells of 
the aortic intima, also differs between BAV and TAV patients and is related to aortic 
size.
109, 172, 173
 Hope et al. reported an association between BAV and elevated shear 
stress and proposed that elevated and asymmetrical shear stress constitutes an increased 
risk of aortic dilatation. Interestingly, Cheng et al. showed in a mouse model that 
“lowered shear stress and vortices” are associated with larger and more vulnerable 
atherosclerotic lesions whereas regions of increased shear stress are protected.
174
 
Furthermore, lowered shear stress/vortices were associated with loss of smooth muscle 
cells, increased expression of proatherogenic inflammatory mediators, and MMP 
activity. These molecular findings are similar to those of studies investigating aneurysm 
formation in TAV patients 
100, 157
 (Study IV). Abnormal flow patterns are not restricted 
to BAV patients but are also seen in TAV patients with aortic valve stenosis and are 
suggested to be the cause of post-stenotic aortic dilatation.
172
 However, in the present 
cohort of cardiac surgery patients, the combination of a TAV, aortic valve stenosis and 
dilatation of the ascending aorta was extremely rare (Study I, II). It is possible that 
abnormal flow patterns and elevated shear stress caused by a BAV (non-calcified or 
stenotic) or a stenotic TAV induces aneurysm formation in BAV patients but not TAV 
patients. Whether this phenomenon is explained by an inherent wall weakness and/or 
by long-standing hemodynamic stress on the aortic wall caused by the malformed valve 
is not known. 
 
Della Corte et al. showed that the “cusp opening angle” of the fused leaflet in BAV 
patients with the RL configuration is narrower than the corresponding TAV leaflets and 
that this causes an altered flow across the BAV. The authors propose measurement of 
the “cusp opening angle” as a novel method for quantifying the abnormal opening of a 
BAV.
175
 It was also shown that the flow jet stream in BAV patients is skewed and that 
the “cusp opening angle” is inversely correlated to ascending aortic diameter, and age, 
and also correlated with the annual rate of aortic enlargement. It is important to 
remember that an enlarged aorta at baseline is a predictor of further dilatation of the 
aorta and aneurysm formation 
2, 176
 and as frequently shown, BAV patients, even if 
comparable in other parameters, consistently have larger aortas than their TAV 
counterparts.
56, 119, 147
 This was also true in the study by Della Corte et al. in which not 
only the “cusp opening angle” but also the diameter of the sinus of Valsalva and body 
surface area (but not BAV or TAV) were predictors of ascending aortic dimensions in 
multivariable regression analyses. It has not been clarified whether a dilated aorta 
causes abnormal flow or vice versa.
109, 173, 177
. 
 
“Nested helical flow”, with different directions according to BAV phenotype (RL and 
RN), is present in BAV patients but not in TAV patients.
116
 This finding led to the 
hypothesis that flow differences related to BAV phenotype might explain differences in 
aortic morphology.
178
 Nathan et al., in accord with other investigators,
172, 173
 showed 
that wall stress differs between BAV and TAV; however an association between BAV 
phenotype and differences in wall stress could not be established.
142
 The present 
finding that, in spite of differences in the prevalence of various BAV phenotypes, the 
distribution of BAV phenotypes was similar  regardless of aortic morphology (i.e., non-
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dilated, aneurysm, and ectasia) in patients scheduled for cardiac surgery is in agreement 
with the experimental findings of Nathan et al. (Study I, II). 
 
Histological differences related to ascending aortic location with reference to valve 
morphology, valve pathology, and aortic morphology were not investigated in this 
thesis but constitute an interesting aspect of BAV disease. Russo et al. reported a 
greater prevalence of more severe medial degeneration in BAV patients with RL than 
those with RN leaflet fusion,
93
 and it has been suggested that these histological findings 
might be related to the orientation of the flow jet across the valve.
178
 Cotrufo et al. 
demonstrated differences in the expression of extracellular matrix proteins related to 
valve pathology, aortic morphology, and aortic location (convex or concave portion of 
the ascending aorta) but not to valve morphology (i.e., BAV/TAV).
179
 The finding that 
smooth muscle cell apoptosis in BAV patients with aortic valve stenosis differes with 
aortic location (concavity/convexity) even when the aorta is non-dilated corroborated 
the work of Cotrufo et al.
157
 Based on their findings, Cotrufo et al. proposed that the 
aortic wall in BAV patients may have an impaired ability to adapt to the increased 
hemodynamic stress.
179
 Interestingly, in an analysis of flow-mediated gene expression 
in the ascending aorta Maleki et al. found evident differences between BAV and TAV 
patients.
117
 Further experimental analyses revealed that a large portion of the genes of 
interest was related to angiogenesis and/or wound healing, and the expression pattern 
was indicative of defective wound healing in BAV patients. The quality, stability, and 
thereby strength of the aortic media collagen has been suggested to be abnormal in 
BAV patients in comparison with TAV patients, and this is likely due to impaired 
synthesis and post-translational modification of collagen.
180
 In the work by Cotrufo et 
al., differences in collagen expression related to valve pathology were found; levels of 
both collagen I and collagen I mRNA were reduced in BAV patients with valve 
regurgitation, whereas BAV patients with valve stenosis had a decreased amount of 
collagen protein but similar amounts of mRNA as controls.
179
 The authors speculated 
that BAV patients with valve stenosis may have an impaired ability to adapt to 
increased stress, possibly due to an abnormal turnover of collagen. Thus, the two 
dominating theories of what causes BAV-associated aortic dilatation (i.e., genetics and 
hemodynamics) seem to intertwine.  
 
Le Canna et al. reported no differences in the progression of aortic dimensions between 
BAV and TAV patients with dilated aorta but without significant valve pathology.
181
 It 
has been argued that the lack of differences between these groups indicate that BAV 
patients do not have an inherent wall weakness.
182
 Beroukhim et al. investigated 
baseline aortic dimensions and progression rates in children without valve pathology 
and, in contrast to La Canna et al., found significant differences between BAV and 
TAV individuals.
119
 In view of recent findings of differences in flow 
109
 and shear stress 
173
 related to valve morphology and the notion that a non-calcified BAV is inherently 
stenotic 
60
 the result of La Canna et al. may indicate that there is an intrinsic (but 
individual) genetic susceptibility for aortic dilatation in the presence of hemodynamic 
stress in BAV patients since not all BAV individuals develop ascending aortic dilation. 
In agreement with previous work,
126
 in this thesis, patients with UAV were younger 
than BAV patients who in turn were younger than TAV patients (TAV, 69 ± 11; BAV, 
60 ± 12; UAV, 48 ± 9 years respectively, p < 0.0001). Patients with ascending aortic 
aneurysm and a true BAV or BAV-RN were younger than those with BAV-RL (RL 64 
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± 10; RN 59 ± 7; TB 54 ± 12 years respectively, p ≤ 0.03), and patients with UAV were 
younger that BAV-RN (UAV 50 ± 6; RN 59 ± 7 years respectively, p = 0.02). 
Moreover, the dimensions of the sinus of Valsalva, sinotubular junction, and aortic root 
height were larger in patients with aneurysm and true BAV than in those with BAV-RL 
or BAV-RN (Study I). It is likely that the different valve morphologies (BAV, BAV 
phenotype, and UAV) constitute a spectrum of the same malformation, and the 
differences in age and aortic dimensions suggest a heterogeneous genetic influence that 
is related to valve morphology and BAV phenotype. It has been proposed that 
dilatation of the aortic root in BAV patients is a more genetically influenced phenotype 
than other BAV-associated aortic morphologies based on the “root type” being fairly 
uncommon and mainly found in males with aortic valve regurgitation.
150, 178
 Nistri et al. 
has showed that valve regurgitation is the predominant valve pathology in young males 
with BAV and that the associated aortic dilatation in these patients is related to the 
presence of valve regurgitation but not to the severity of valve pathology.
54
 In accord, 
in this thesis, valve regurgitation was rare in females regardless of valve morphology 
and aortic morphology (male to female ratio in patients without coronary artery disease: 
with valve regurgitation, 4.4:1 vs. without 1.4:1, p < 0.0001; with valve stenosis 1.4:1 
vs. without 3.6:1, p < 0.0001). Roberts et al. has further found that BAV patients with 
aneurysmatic aortas and valve regurgitation have a more pronounced loss of elastic 
fibres than those with valve stenosis.
183
  
 
The idea of impaired wound healing and a reduced ability to adapt to stress in BAV 
patients conjoins the two dominating theories of what causes BAV-associated aortic 
dilatation. An aorta with an inborn weakness, an insufficient capacity to adapt to 
hemodynamic stress, and an impaired regenerative ability is likely susceptible to 
dilatation when subjected to abnormal hemodynamic stress.  
 
 
 CLINICAL IMPLICATIONS  6.7
With a prevalence of 1-2% in the population and an estimated need for surgical 
intervention in 25-50% of cases, the malformation has major medical implications. 
Many aspects of the natural history of BAV and BAV disease remain uncertain and this 
topic is difficult to address due to the heterogeneous character of both healthy and 
diseased BAV individuals.
56, 70, 102, 103, 118, 137, 181, 184-191
 Not all BAV individuals will 
develop valve and/or aortic pathology and to prospectively follow children with BAV 
or TAV into adulthood, taking BAV phenotype, severity of valve pathology, aortic 
morphology, aortic pathology, other comorbidities (e.g., coronary artery disease), and 
effects of possible interventions into account, is probably neither feasible nor ethical.  
 
The finding of this thesis that ascending aortic dilatation is rarely associated with aortic 
valve stenosis in TAV patients but is frequently seen in BAV patients with valve 
stenosis may, from a clinical standpoint, help guide selection of the appropriate surgical 
treatment strategy for these patients. The fate of a non-replaced aorta following aortic 
valve replacement is uncertain and there is an on-going debate concerning the 
appropriate timing and extent of aortic replacement in BAV patients.
102, 103, 153, 186, 189, 
190, 192-197
 The results of the present work do not support the proposal that BAV 
phenotype is a predictor of preoperative aortic dilatation in BAV patients scheduled for 
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cardiac surgery. The finding that there is a small likelihood of concomitant dilatation of 
the descending and/or abdominal aorta in BAV patients with dilated ascending aorta 
could be used to reassure patients and to guide the surveillance strategy. As coronary 
artery disease is rarely associated with ascending aortic dilatation, this finding may be 
grounds for a less invasive preoperative evaluation of the coronary arteries than a 
coronary angiogram (i.e., computed tomography angiogram) in patients with ascending 
aortic dilatation, especially in patients with a BAV.  
 
Current guidelines state that aortic surgery is recommended when the dimension of the 
aortic root and/or the ascending aorta exceeds 45 mm in BAV patients scheduled for 
aortic valve surgery.
63, 198, 199
 With a normally functioning BAV aortic replacement is 
recommended when aortic dimensions exceed 50 mm or when the growth rate exceeds 
2-5 mm per year. However, the recommendations of the guidelines are also debated.
145, 
182, 188, 191, 200
 Regardless, it is important to recognise the heterogeneity of BAV disease 
and thus evaluate each patient individually. In addition to conventional preoperative 
and perioperative considerations in cardiac surgery patients, factors that have a major 
impact in BAV disease should be recognised and considered, and thus an appropriate 
treatment and surveillance strategy can be tailored for each BAV individual.  
 
 
 STUDY LIMITATIONS 6.8
The patients constituting the study population of this thesis are all cardiac surgery 
patients and therefore the results not applicable to a non-diseased BAV population. 
Furthermore, the single centre setup might reduce the generalisability of the results. 
Moreover, the studies of this thesis were all cross-sectional as opposed to longitudinal 
and are therefore not designed to answer questions concerning the progression of 
pathology. The multifaceted character of BAV disease entails a statistical challenge 
where outcome measures are possibly dependent on several co-factors. Set cut-off 
values for aortic dilatation differed between BAV and TAV patients based on surgical 
guidelines. It should also be emphasised that in the echocardiographic evaluation of the 
study participants, the transthoracic examinations were performed on awake patients 
whereas the transesophageal examinations were performed on anesthetised patients, 
and blood pressure and loading conditions differs between these two conditions.  
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7 CONCLUSIONS 
 
More than 50% of patients scheduled for aortic valve and/or ascending aortic surgery 
have a BAV. BAV patients are approximately 10 years younger than TAV patients at 
the time of surgery. Patients with additional coronary artery disease are older than 
patients without regardless of BAV or TAV. Ascending aortic aneurysm is 
substantially more common in BAV patients than in TAV patients while ectasia is 
equally common regardless of valve morphology. With ascending aortic dilatation, 
aortic valve stenosis is almost exclusively associated with BAV whereas aortic valve 
regurgitation is associated with either BAV or TAV.  
 
 
The dimensions of the left ventricular outflow tract and annulus are larger in BAV 
patients than in TAV patients, regardless of aortic morphology. The relative 
distributions of aortic aneurysm and ectasia are not related to BAV phenotype. 
 
The combination of aortic valve stenosis and ascending aortic aneurysm is common in 
BAV patients but virtually non-existent in TAV patients. Increasing severity of valve 
pathology is associated with smaller aortic dimensions. The distribution of valve 
pathology does not differ with the various BAV phenotypes. 
 
BAV patients with ascending aortic aneurysm have smaller dimensions of the distal 
aorta than the corresponding group of TAV patients. Concomitant dilatation of the 
descending aorta is predominantly found in TAV patients. 
 
Expression of matrix metalloproteinase 14 and 19 is associated with ascending aortic 
aneurysm formation in TAV patients, but not BAV patients.  
 
BAV patients with aortic valve pathology and/or ascending aortic dilatation rarely have 
concomitant coronary artery disease. Ascending aortic dilatation and coronary artery 
disease seldom co-exist regardless of valve morphology.  
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